












Rachel Katherine Goggin 
Bachelor of Medical Science (Honours) 
Bachelor of Medicine, Bachelor of Surgery 
 
Department of Otolaryngology, Head and Neck Surgery 
Adelaide Medical School 
The University of Adelaide, Adelaide, Australia 
 











To my long-suffering parents Mary and Michael and to my 


















































Table of contents 
 
Thesis declaration .................................................................................................................... 2 
Acknowledgements .................................................................................................................. 3 
Publications arising from this thesis ...................................................................................... 5 
Presentations arising from this thesis .................................................................................... 6 
Abbreviations ........................................................................................................................... 7 
List of tables............................................................................................................................ 10 
List of figures .......................................................................................................................... 12 
Thesis summary ..................................................................................................................... 14 
Systematic review of the literature ....................................................................................... 17 
1.1 Chronic rhinosinusitis .................................................................................................. 17 
1.2 Theories of the aetiology and pathogenesis of chronic rhinosinusitis ..................... 18 
1.2.1 The bacterial hypothesis .......................................................................................... 18 
1.2.2 The immune hypothesis ........................................................................................... 21 
1.2.3 The fungal hypothesis .............................................................................................. 22 
1.2.4 The viral hypothesis and the role of interferons ...................................................... 23 
1.3 Disease severity in chronic rhinosinusitis .................................................................. 32 
1.3.1 Subjective measurement .......................................................................................... 32 
1.3.2 Objective measurement ........................................................................................... 35 
1.4 Virology of the upper aerodigestive tract .................................................................. 39 
1.4.1 Adenovirus............................................................................................................... 39 
1.4.2 Influenza virus ......................................................................................................... 41 
1.4.3 Coronavirus ............................................................................................................. 42 
1.4.4 Parainfluenza virus .................................................................................................. 43 
1.4.5 Rhinovirus ............................................................................................................... 44 
1.4.6 Respiratory syncytial virus ...................................................................................... 45 
1.4.7 Metapneumovirus .................................................................................................... 47 
1.4.8 Bocavirus ................................................................................................................. 48 
1.4.9 Enterovirus............................................................................................................... 48 
 
 
1.4.10 Herpesviridae ........................................................................................................ 49 
1.5 Viral-bacterial coinfection ........................................................................................... 51 
1.5.1 Interactions in the lower respiratory tract ................................................................ 51 
1.5.2 Effects on epithelial barrier function ....................................................................... 52 
1.5.3 Effects on bacterial binding ..................................................................................... 53 
1.5.4 Effects on innate and adaptive immunity ................................................................ 53 
1.5.5 Effects on the respiratory microenvironment .......................................................... 55 
1.5.6 Direct viral-bacterial interactions ............................................................................ 55 
1.5.7 Interactions in the upper respiratory tract ................................................................ 56 
1.6 Viral collection and processing methods .................................................................... 60 
1.7 Viruses and chronic rhinosinusitis ............................................................................. 63 
1.7.1 Conventional URTI-causing viruses and CRS ........................................................ 63 
1.7.2 The Herpesviridae and CRS .................................................................................... 68 
1.8 The bacterial microbiome of chronic rhinosinusitis ................................................. 71 
1.9 Cellular infiltrates and chronic rhinosinusitis ........................................................... 74 
1.9.1 Eosinophilia and CRS .............................................................................................. 74 
1.9.2 T lymphocytes and CRS .......................................................................................... 75 
Summary of the systematic review of the literature ........................................................... 76 
Aims ......................................................................................................................................... 78 
Comparative viral sampling in the sinonasal passages; different viruses at different sites
.................................................................................................................................................. 79 
Statement of authorship .................................................................................................... 79 
2.1 Abstract ......................................................................................................................... 81 
2.2 Introduction .................................................................................................................. 82 
2.3 Materials and methods ................................................................................................ 84 
2.3.1 Study participants .................................................................................................... 84 
2.3.2 Sampling and processing ......................................................................................... 84 
2.3.3 PCR/RT-PCR........................................................................................................... 85 
2.3.4 Statistical analysis.................................................................................................... 90 
2.4 Results ........................................................................................................................... 91 
2.4.1 Patient characteristics .............................................................................................. 91 
2.4.2 Viral detection and analysis ..................................................................................... 91 
2.5 Discussion ...................................................................................................................... 94 
 
 
The presence of virus significantly associates with chronic rhinosinusitis disease severity
.................................................................................................................................................. 98 
Statement of authorship .................................................................................................... 98 
3.1 Abstract ....................................................................................................................... 100 
3.2 Introduction ................................................................................................................ 101 
3.3 Methods ....................................................................................................................... 102 
3.3.1 Study participants and data collection ................................................................... 102 
3.3.2 Viral sampling and processing .............................................................................. 102 
3.3.3 Viral PCR/RT-PCR ............................................................................................... 103 
3.3.4 Statistical analysis.................................................................................................. 103 
3.4 Results ......................................................................................................................... 105 
3.4.1 Patient characteristics and viral detection ............................................................. 105 
3.4.2 Correlation with disease severity ........................................................................... 106 
3.4.3 Viral species detection and seasonal spread .......................................................... 107 
3.5 Discussion .................................................................................................................... 110 
Association between viral infection and increased mucosal eosinophils and CD8+CD103+ 
T cells in chronic rhinosinusitis. ......................................................................................... 113 
Statement of authorship .................................................................................................. 113 
4.1 Introduction ................................................................................................................ 116 
4.2 Methods ....................................................................................................................... 117 
4.2.1 Study participants .................................................................................................. 117 
4.2.2 Viral sampling, processing and analysis ................................................................ 118 
4.2.3 Mucosal sampling, processing and analysis .......................................................... 118 
4.2.4 Statistical analysis.................................................................................................. 120 
4.3 Results ......................................................................................................................... 121 
4.3.1 Patient characteristics ............................................................................................ 121 
4.3.2 Viral detection and analysis ................................................................................... 122 
4.4 Discussion .................................................................................................................... 127 
Association between viral presence and changes in the bacterial microbiome in chronic 
rhinosinusitis ........................................................................................................................ 129 
Statement of authorship .................................................................................................. 129 
5.1 Abstract ....................................................................................................................... 131 
5.2 Introduction ................................................................................................................ 132 
5.3 Materials and methods .............................................................................................. 134 
 
 
5.3.1 Study participants .................................................................................................. 134 
5.3.2 Viral sampling, processing and analysis ................................................................ 134 
5.3.3 Bacterial sampling and processing ........................................................................ 135 
5.3.4 Bacterial 16S-sequencing ...................................................................................... 136 
5.3.5 Bioinformatic pipeline ........................................................................................... 136 
5.4 Results ......................................................................................................................... 139 
5.4.1 Patient characteristics ............................................................................................ 139 
5.4.2 Viral detection ....................................................................................................... 139 
5.4.3 Bacterial microbiome outcomes: taxonomy .......................................................... 140 
5.4.4 Viral covariates as predictors of bacterial taxa abundances .................................. 142 
5.4.5 Viral covariates as predictors of bacterial diversity and stability .......................... 143 
5.5 Discussion .................................................................................................................... 144 
Thesis synopsis and future directions ................................................................................ 147 





















I certify that this work contains no material which has been accepted for the award of any 
other degree or diploma in my name, in any university or other tertiary institution and, to the 
best of my knowledge and belief, contains no material previously published or written by 
another person, except where due reference has been made in the text. In addition, I certify 
that no part of this work will, in the future, be used in a submission in my name, for any other 
degree or diploma in any university or other tertiary institution without the prior approval of 
the University of Adelaide and where applicable, any partner institution responsible for the 
joint-award of this degree.  
 
I acknowledge that copyright of published works contained within this thesis resides with the 
copyright holder(s) of those works.  
 
I give permission for the digital version of my thesis to be made available on the web, via the 
University’s digital research repository, the Library Search and also through web search 
engines, unless permission has been granted by the University to restrict access for a period 
of time.  
 
I acknowledge the support I have received for my research through the provision of an 









No man is an island, and this thesis is a glowing example. There is a myriad of individuals 
without whom I could never have completed this work, and here I will name just a few. 
 
Firstly I would like to thank my primary supervisor Sarah Vreugde and my co-supervisors 
Alkis Psaltis and PJ Wormald. Your ideas, mentorship, teaching, encouragement and support 
have been overwhelming. The wonderful department you have created is testament not just to 
your illustrious careers and incredible capabilities as academics and surgeons, but to the way 
you see your team and co-workers as members of a family, far from just a group of staff. I 
have been so very lucky to have worked for you and you will all be sorely missed. If I can 
take even a small piece of your skills and attitudes away with me I will have achieved a 
momentous amount. 
 
To my unofficial advisors and mentors Eric Gowans and Seweryn Bialasiewicz; how a 
clinician like me could ever have navigated the world of virology without your excellent 
guidance remains a mystery. 
 
To the research staff in the ENT department at the Basil Hetzel Institute; Catherine Bennett, 
Mahnaz Ramezanpour, Clare Cooksley and Andrew Hayes. Your assistance, teaching and 
patience have been invaluable, and it has been an absolute pleasure to spend the last two 
years with you.  
 
To my brothers-in-arms, the other researchers and registrars in the ENT department at the 
Queen Elizabeth Hospital; Sathish Paramasivan, Stephen Kao, Ahmed Bassiouni, Rajan 
4 
 
Vediappan, Aden Lau, Lisa Cherian, Mian Ooi, Michael Gouzos, Giri Krishnan, Ashley 
Twigger, Stephanie Fong, Annika Mascarenhas, Beula Panchatcharam and Jae Murphy. 
Whether it be assistance in the lab, in theatre, in clinic, following up patients, reviewing 
manuscripts or just listening to my rants at the Woody on a Friday afternoon, your 
contributions have been enormous. It has been my great fortune to have met, worked and 
become friends with you all. Dish deserves a special mention; there at the beginning, there in 
the trenches, and no doubt he will still be there in the end. I can think of no better friend and 
colleague with whom to have spent the last decade. 
 
To the University of Adelaide; my sincere gratitude for the opportunities and financial 
support that have allowed me to undertake and complete this project. 
 
My gratitude to our patients, who have so graciously accepted so many of the unpleasant 
things I have asked of them. 
 
And finally to my parents, Mary and Michael, the dynamic duo, and to my husband Patrick. 
The endless sacrifices you have made for me, the overseas and interstate relocations, the 
unwavering belief in my abilities, the sometimes-unwelcome but eventually-appreciated 
advice, the patience when “I got caught up”, the hours of “Okay, I just want to vent” phone 







Publications arising from this thesis 
 
Comparative viral sampling in the sinonasal passages; different viruses at different sites 
Goggin RK, Bennett CA, Bassiouni A, Bialasiewicz S, Vreugde S, Wormald PJ and Psaltis 
AJ. 
Front. Cell. Infect. Microbiol. 2018 Sep 19;8:334. 
 
The presence of virus significantly associates with chronic rhinosinusitis disease severity 
Goggin RK, Bennett CA, Bialasiewicz S, Vediappan RS, Vreugde S, Wormald PJ and Psaltis 
AJ. 
Allergy. 2019 Aug 74(8):1569-1572 
 
Association between viral infection and increased mucosal eosinophils and CD8+CD103+ 
T cells in chronic rhinosinusitis 
Goggin RK, Bennett CA, Ramezanpour M, Hu H, Fenix K, Javadiyan S, Bialasiewicz S, 
Bassiouni A, Wormald PJ, Psaltis AJ and Vreugde S. 
Int Forum All Rhinol. Accepted for publication March 2020, final citation to be advised. 
 
Association between viral presence and changes in the bacterial microbiome in chronic 
rhinosinusitis 
Goggin RK, Bennett CA, Cooksley CM, Bassiouni A, Bialasiewicz S, Wormald PJ, Vreugde 
S and Psaltis AJ. 





Presentations arising from this thesis 
 
The virome in chronic rhinosinusitis 
The Australian Society of Otolaryngology, Head and Neck Surgery Annual Scientific 
Meeting 
Perth, Australia, March 2018 
 
Association between viral presence and chronic rhinosinusitis severity 
The Queen Elizabeth Hospital Research Exposition 
Adelaide, Australia, October 2018 
 
The presence of virus significantly associates with chronic rhinosinusitis disease severity 
American Rhinologic Society Annual Meeting 
Top abstracts section 













ADSS – Adelaide Disease Severity Score 
AdV – Adenovirus 
AEC – Airway epithelial cell 
AJ – Adherens junction 
ALI – Air-liquid interface 
AFS – Allergic fungal sinusitis 
BoV – Bocavirus 
CF – Cystic fibrosis 
CMV – Cytomegalovirus 
COPD – Chronic obstructive pulmonary 
disease 
CoV – Coronavirus 
CPE – Cytopathic effects 
CRS – Chronic rhinosinusitis 
CRSsNP – Chronic rhinosinusitis without 
nasal polyps 
CRSwNP – Chronic rhinosinusitis with 
nasal polyps 
CSS – Chronic Sinusitis Survey 
CT – Computed tomography 
Ct – Cycle threshold 




DKO – Double knock-out 
EBV – Epstein Barr virus 
EnV – Enterovirus 
ER – Endoplasmic reticulum 
ERV3 – Endogenous retrovirus 3 
EPS – Exopolysaccharide  
FESS – Functional endoscopic sinus 
surgery  
H and E – Haematoxylin and eosin 
H. influenzae - Haemophilus influenzae 
HA – Haemagglutinin 
hB/NEC – Human bronchial/nasal 
epithelial cell 
HHV6 – Human herpes virus 6 
HPV – Human papilloma virus 
HSV – Herpes simplex virus 
hTeRT – Human telomerase reverse-
transcriptase 
ICAM-1 - Intercellular adhesion molecule 
1 
IFN – Interferon 
IFNLR – Interferon lambda receptor 
IL – Interleukin 
8 
 
IM/T – Inferior meatus/turbinate 
LKS – Lund Kennedy score 
LMS – Lund MacKay score 
L/URT – Lower/upper respiratory tract 
L/URTI – Lower/upper respiratory tract 
infection 
M. catarrhalis – Moraxella catarrhalis 
MHC – Major histocompatibility complex 
MM/T – Middle meatus/turbinate 
MLK – Modified Lund Kennedy score 
MPV – Metapneumovirus 
N. meningitidis – Neisseria meningitidis 
NA – Neuraminidase 
NAAT – Nucleic acid amplification tests 
OMU – Ostiomeatal unit 
P. aeruginosa – Pseudomonas aeruginosa 
PAFR – Platelet activating factor receptor 
PCR – Polymerase chain reaction 
PIV – Parainfluenza virus 
PMBC – Peripheral mononuclear blood 
cell 
PND – Post-nasal drip 
PPE – Personal protective equipment 
PRR – Pattern recognition receptor 
POSE – Perioperative Sinonasal 
Endoscopic score 
PVOD – Post-viral olfactory dysfunction 
QOD – Questionnaire of Olfactory 
Disorders 
QoL – Quality of life 
RSDI – Rhinosinusitis Disability Index 
RSOM-31 – 31-Item Rhinosinusitis 
Outcome Measure 
RSV – Respiratory syncytial virus 
RT-PCR – Reverse transcription 
polymerase chain reaction 
RV – Rhinovirus 
S. aureus – Staphylococcus aureus 
S. pneumoniae – Streptococcus 
pneumoniae 
SAg – Superantigen 
SCT – Sinusitis Control Test 
SLPI – Secretory leucocyte protease 
inhibitor 
SNOT-22 – Sino-Nasal Outcome Test 22 
TAP – Transporter associated with antigen 
processing 
Th – T helper type 
TJ – Tight junction 
9 
 
TLR – Toll-like receptor 
TNF – Tumour necrosis factor 
Trm cells – Tissue-resident memory T 
cells 
VAS – Visual Analogue Scale 
VP – Virus-positive 
VN – Virus-negative 
VZV – Varicella zoster virus 






















List of tables 
 
Table 1.1 Known Herpesviridae clinical manifestations and possible systemic antiviral 
treatments available. 
Table 1.2 Summary of published virome studies. 
Table 1.3 Summary of investigation of CRS and the Herpesviridae. 
Table 2.1 Target gene, probe and primer details for DNA viruses. 
Table 2.2 Target gene, probe and primer details for RNA viruses. “+” indicates a locked 
nucleic acid (eg. +A is a locked nucleic adenine analogue). 
Table 2.3 Summary of patient demographics and characteristics. 
Table 2.4 Viral species identified at middle and inferior meatuses. 
Table 3.1 Summary of patient demographics and characteristics for viral analysis. 
Table 3.2 Details of virus-positive patients, including viral species, mean severity scores and 
cycle threshold values. *Indicates viral species for which only one patient was positive, so 
mean score not able to be calculated. Instead that one patient’s scores have been recorded. 
Table 3.3 Details of viral species, strains and patient diagnoses. 
Table 4.1 Summary of patient demographics and characteristics for eosinophil and T 
lymphocyte analysis. 
Table 4.2 Mean cell counts. “VP” indicates virus-positive, “VN” indicates virus-negative. 
Table 4.3 Viral species identified. 
Table 4.4 Poisson model of eosinophil average. 
Table 4.5 Poisson model of CD8+ T cell average. 
Table 4.6 Poisson model of CD103+ T cell average. 
Table 4.7 Poisson model of DP Trm cell average. 
Table 5.1 Summary of patient demographics and characteristics. 
Table 5.2 Details of viral species and patient diagnoses. 
11 
 
Table 5.3 Summary of most abundant bacterial genera. “MRA” indicates mean relative 


























List of figures 
 
Figure 1.1 Scanning electron micrograph of S. aureus biofilms on the inner surface of a 
needleless connector, showing both cellular material and EPS matrix (reproduced with 
permission). 
Figure 1.2 Downstream effects of virus-induced IFN expression. 
Figure 1.3 Sino-Nasal Outcome Test 22. 
Figure 1.4 Adelaide Disease Severity Score. 
Figure 1.5 Visual Analogue Scale. 
Figure 1.6 Lund MacKay scoring system. 
Figure 1.7 Perioperative Sinonasal Endoscopic scoring system. 
Figure 1.8 Discharge, Inflammation and Polyp scoring system. 
Figure 1.9 Lund Kennedy scoring system. 
Figure 1.10 Modified Lund Kennedy scoring system. 
Figure 1.11 Electron microscope image of adenovirus, reproduced with permission. 
Figure 1.12 Electron microscope image of influenza virus, reproduced with permission. 
Figure 2.1 Cytology brushing of sinonasal mucosa. 
Figure 3.1 Detection of virus by PCR in controls and CRS patients. Number of patients 
where virus was detected and not detected in controls, CRSsNP and CRSwNP. Comparison 
of positivity of virus detected, * p<0.05, Chi-square test. 
Figure 3.2 Objective (top) and subjective (bottom) disease scores in virus negative and 
virus positive patients. Grouped and compared by diagnosis (control, CRSsNP or 
CRSwNP), * p<0.05, Kruskal-Wallis tests. 




Figure 3.4 Seasonal spread of viral detection by PCR. Grouped by diagnosis (control, 
CRSsNP, CRSwNP). 
Figure 4.1 Mean cell counts of eosinophils (A), CD8+ cells (B), CD103+ cells (C) and 
CD8+ CD103+ Trm cells (D) in virus negative (-) and virus positive (+) controls (n = 6), 
CRSsNP (n = 17 top left, 16 elsewhere) and CRSwNP (n = 10 top left, 9 elsewhere) patients.   
* p<0.05, ** p<0.005, *** p<0.0005, **** p<0.0001 
Figure 4.2 Sinonasal mucosa of representative virus negative control (A, C) and virus 
positive CRSwNP patient (B, D). (A, B) Haematoxylin and Eosin stained tissue with 
eosinophils evident in inset image B (arrow indicates eosinophil). (C, D) 
immunofluorescence staining CD8+ T cells red, CD103+ cells green and CD8+ CD103+ Trm 
cells yellow/orange. DAPI stains nuclei blue. 
Figure 5.1 Rarefaction plots. 
Figure 5.2 Relative abundances of the most abundant bacterial genera. “v+” indicates viral 
positivity, “v-“ indicates viral negativity. 
Figure 5.3 Relative abundances of the most abundant bacteria grouped by time since last 













The original research contents of this PhD thesis followed an extensive review of the 
literature in terms of the viral contribution to chronic rhinosinusitis (CRS); this is described in 
chapter one. Understanding of the aetiopathogenesis of the disease is of course integral to 
CRS prevention and treatment. It is also a subject of debate; the roles of bacteria, fungi and 
disordered innate and adaptive immunity have been investigated. Viruses, however, have 
received little attention. A commonly encountered clinical paradigm is that of a patient 
complaining of a viral upper respiratory tract infection (URTI) with the development of CRS 
symptoms thereafter. This has been investigated in population virome studies, however 
results regarding any relationship between viruses and CRS these have been inconsistent. 
Most of these studies have been limited in terms of size, seasonality, viral collection methods 
and the viral species for which investigators assayed. None have validated their collection 
methods or investigated for any association between viral presence and more severe disease. 
In addition to these none have investigated virally-induced changes in the bacterial 
microbiome in CRS. Microbial disarray is an area of burgeoning interest in many chronic 
disease processes, CRS included. Respiratory viruses are known to augment local bacterial 
binding, penetration and persistence. Could virus-induced respiratory epithelial changes be 
contributing to the disease also? 
 
In order to investigate the above, the first step is to establish and validate a robust sinonasal 
viral collection method. This is described in the second chapter of this thesis. Sterile cytology 
brushes under direct endoscopic vision were used for this. 24 patients had two sites sampled 
immediately prior to endoscopic sinus surgery; the middle and inferior meatuses (MM and 
IM). Sample DNA and RNA were extracted and underwent PCR for a panel of common 
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respiratory viruses, including the Herpesviridae and endogenous retrovirus 3 (ERV3). The 
former were chosen for their near-omnipresence in the adult sinuses, and the latter as a 
marker of sample quality. 18/24 were positive for virus in at least one site, including 8 who 
were positive at both sites. Only 3 of those 8 demonstrated the same viral species at both 
sites. 6 showed no virus at either site. All samples demonstrated ERV3 well within published 
ranges indicating adequate sample quality. From this we concluded that the cytobrushes are 
an effective method for viral sampling in the nose and sinuses. We also identified a 
significant discord in viral species between the MM and IM. As such we recommended that 
both sites are sampled in order to gain truly representative data.  
 
The third chapter of this thesis addresses the shortcomings of published population virome 
studies. The collection method detailed in the previous paragraph was used to sample from 
288 patients over the period of one year. Disease severity data were also collected from these 
patients (Sino-Nasal Outcome Test 22 scores (SNOT-22), Adelaide Disease Severity Scores 
(ADSS), Lund MacKay scores (LMS) and Lund Kennedy scores (LKS)). Virus was found to 
be significantly more prevalent in CRS patients without nasal polyps (CRSsNP) than in 
controls or CRS patients with nasal polyps (CRSwNP). Viral presence was also found to be 
associated with significantly worse objective disease (LMS and LKS) but not subjective 
disease (SNOT-22 and ADSS). This is the first and only CRS virome study to encompass all 
subsets of the disease, to allow for seasonal variation in viral presence, and to use validated 
sample collection and processing techniques. We confirmed the long-held suspicion that 
viruses are more common in patients with CRS. As such we highlighted viruses as important 




The fourth chapter investigates the role of eosinophilia and T cell infiltrates in virus-positive 
versus virus-negative CRS and controls. Sinonasal tissue samples were taken and analysed 
for presence of eosinophils, CD8+, CD103+ and CD8+/CD103+ double-positive T cells 
(Trms). CRS was found to be associated with increased eosinophil and CD8+ CD103+ T cells 
in excess of that seen in virus-positive controls, implicating viruses in CRS 
aetiopathogenesis. 
 
The study detailed in the fifth chapter aimed to investigate virus-associated changes in the 
bacterial CRS sinonasal microbiome again by taking brushings of the sinonasal mucosa. 
These were analysed for viral presence and the bacterial microbiome was also characterised, 
using 16S ribosomal RNA gene-targeted amplicon sequencing. Patients were divided into 
control, non-polyp and polyp groups. Half of each group was virus-positive. No significant 
differences were seen in relative abundances of the bacterial genera detected, their diversity 
or stability in any of the groups. A trend towards greater relative abundance of Haemophilus 
spp. was seen in patients reporting a viral illness two to four weeks prior. This early 














Systematic review of the literature 
 
1.1 Chronic rhinosinusitis 
 
Chronic rhinosinusitis (CRS) is an inflammatory disorder of the nasal and paranasal sinus 
mucosa. [1, 2] The pathogenesis remains uncertain, but several external and host-related 
factors are likely at play and a number of theories of have been postulated. [3, 4] Symptoms 
of CRS may include nasal obstruction, facial pain or pressure, anterior rhinorrhoea or post-
nasal drip (PND), and reduction or loss of smell. [2, 3] The presence of two or more of these 
symptoms for twelve weeks or longer defines the syndrome. Two major disease phenotypes 
have been observed: without nasal polyps (CRSsNP) and with nasal polyps (CRSwNP). The 
latter typically causes more severe disease. [5] Published data show CRS is a highly prevalent 
and costly condition; it affects up to 16% of the population, [6, 7] and this is associated with 
substantial health care expenditure. [8-10] Despite great strides having been made in the 
management of CRS in the recent past it has a tendency to persist or recur despite maximal 
medical and surgical treatment, significantly contributing to the aforementioned costs. [3] 
Not only are treatment options expensive, but they are often invasive and not without risks to 
patients. Additionally, rhinosinusitis is the fifth most common diagnosis generating an 
antibiotic prescription worldwide [11] contributing to the development of resistant bacterial 









1.2 Theories of the aetiology and pathogenesis of chronic rhinosinusitis 
 
Despite its prevalence, tendency towards relapse and recalcitrance, and its contribution to 
global health care costs and the development of antibiotic resistance, the aetiopathogenesis of 
CRS has been difficult to elucidate. Only a very small proportion of CRS can be attributed at 
least in part to an existing disorder. These known associations include Wegener’s 
granulomatosis, human immunodeficiency virus, cystic fibrosis (CF) or Kartagener’s 
syndrome. The vast majority of CRS, however, is idiopathic. Much research has been 
directed into the one factor (should such a factor exist) that unites the clinical and 
microbiological manifestations of the disease. A number of theories have been described; 
broadly these are the bacterial hypothesis, the immune hypothesis and the fungal hypothesis, 
with interest building and evidence emerging for a viral hypothesis.  
 
1.2.1 The bacterial hypothesis 
 
The development of the 16S rRNA bacterial sequencing method has revolutionised research 
into the bacterial microbiome throughout the body. Previously poorly-characterised due to 
reliance on more traditional bacterial culture methods, the sinonasal microbiome is now at the 
forefront of CRS research. Bacterial burden is becoming less of a focus in favour of relative 
abundance and diversity, [14] and the role of commensal bacteria is under scrutiny. There is a 
paucity of large-scale investigation into the CRS bacterial microbiome in the published 
literature, but theories regarding the potentially protective role of commensal bacteria and the 
disarray caused by overgrowth of more traditionally pathogenic bacteria abound in other 
organ systems. [15] Of particular interest to this thesis would be the potential for viral 
pathogens to initiate a disease-causing bacterial microbiome imbalance. Extensive study of 
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the sinonasal bacterial microbiome in health and disease is currently underway and has 
exciting implications for treatment of the disease. This is discussed in greater depth in “1.8 
The bacterial microbiome of chronic rhinosinusitis”. 
 
Pre-dating these new molecular bacterial detection techniques however, Staphylococcus 
aureus (S. aureus) overgrowth has long been seen as a major contributor to CRS. [16] These 
bacteria in particular (along with Pseudomonas aeruginosa (P. aeruginosa), Streptococcus 
pneumoniae (S. pneumoniae), Haemophilus influenzae (H. influenzae) and Moraxella 
catarrhalis (M. catarrhalis)) have been heavily implicated in the formation of biofilms. 
Biofilms are communities of micro-organisms surrounded by an exopolysaccharide (EPS) 
matrix (figure 1.1). They are nigh-impossible to detach from the host surface and have the 
ability to slow their metabolic rate, allowing them to evade host immune responses and 
antibiotics, and to persist despite environments hostile for bacterial growth. [17] Planktonic S. 
aureus has been observed in up to 50% of CRS patients [18, 19] with S. aureus biofilms seen 
in 25 to 100%. [20] Theoretically biofilm defence-evasion and hostile-proliferation properties 
would lend them a unique ability to act as a bacterial reservoir. This may allow them to 
contribute to disease persistence and the downstream effects of simple planktonic bacterial 





Figure 1.1 Scanning electron micrograph of S. aureus biofilms on the inner surface of a 
needleless connector, showing both cellular material and EPS matrix, reproduced with 
permission. [21] 
 
S. aureus has an additional potential mechanism by which to cause harm in CRS; that of 
superantigen (SAg) exotoxin production. SAgs are produced by some bacteria and induce 
widespread non-specific T-cell activation and subsequent massive cytokine release from 
multiple immune cell types. S. aureus SAgs are associated with approximately 50% of 
CRSwNP (the more severe subset of the disease) and not with CRSsNP or controls. This is 
despite S. aureus colonisation in CRSsNP and controls. [22] The lack of a demonstrable SAg 
effect in such a large proportion of CRSwNP patients has led to postulation that these not be 
causative entities, but rather exacerbators of a pre-existing inflammatory imbalance with a 




1.2.2 The immune hypothesis 
 
Interference with normal host defences by CRS can occur at a number of levels; these include 
the mechanical and immune barriers to pathogens. More specifically the mechanical barrier 
encompasses mucus, the muco-ciliary escalator, and tight and adherens junctions (TJs and 
AJs) between cells. The innate immune barrier includes cytokine-mediated immune cell 
recruitment, activation of complement, identification and removal of foreign material and 
debris. The adaptive immune barrier includes antigen presentation and recognition of non-
self, generation of pathogen-specific elimination processes, and development of 
immunological memory. Interference with any of these may be caused by a number of host or 
environmental factors, but defects in any/all of these elements may result in disruption of the 
microbiome, increased exposure to pathogens, and/or an exaggerated compensatory innate 
and/or adaptive response, which can be damaging themselves. [23] 
 
CF patients demonstrate a highly defective muco-ciliary escalator and also an abnormally 
high incidence of CRS, [24] as do CF gene mutation carriers who do not manifest the disease 
clinically. [25] In non-CF CRS patients the muco-ciliary escalator has also been shown to be 
defective. [26] TJs are weaker in vitro in CRS cells than in control cells, [27] and permeation 
of foreign material across this leaky barrier has also been demonstrated. [28] 
 
A wealth of innate antimicrobials and associated molecules are produced in response to 
sinonasal pathogens, and secretion or activity of many of these are defective in CRS. 
Examples include lactoferrin (a non-specific antimicrobial), S100s (psoriasin and 
calprotectin, with roles in wound healing) and PLUNC (an antimicrobial with anti-biofilm 
properties). Also implicated are the pattern recognition receptor (PRR, responsible for 
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signalling pathways leading to innate antimicrobial secretion), the toll-like receptors (TLRs, 
part of the PRR family), bitter taste receptors and interleukin 22 (IL-22). Reports, however, 
are conflicting as to the magnitude and effect of these changes and their roles in CRSsNP 
versus CRSwNP. [29-33] 
 
With regards the adaptive immune response in CRSwNP, a T helper type (Th-) 2 profile 
predominates. This is characterised by excessive eosinophilia, neutrophilia, IL-4, IL-5, IL-10, 
IL-13, mast cells, B lymphocytes, a reduction in collagen in favour of fibrin, and significant 
local oedema. [34] Conversely CRSsNP is more classically associated with a Th-1 skewed 
response. [35] However this is not uniform and can vary in population subtypes. For 
example, CRSwNP patients with CF exhibit more neutrophilia and a Th-17 cytokine 
predilection. [36] Multiple attempts have been made to classify CRS based on T-cell and 
cytokine profiles with no consensus reached. Despite a lack of concrete conclusions these 
studies do, however, indicate that a defective adaptive immune response is at play in the 
aetiopathogenesis of CRS. 
 
1.2.3 The fungal hypothesis 
 
In the late 1990s and early 2000s interest in the role of fungal elements and their potential 
ability to incite and drive CRS was sparked by research in the USA. In a cohort of 210 CRS 
patients, 96% had fungus cultured from their nasal secretions. Almost all of these went on to 
meet the diagnostic criteria for allergic fungal sinusitis (AFS) with regards histological and/or 
culture analysis. [37] This highlighted fungal pathogens as promising factors uniting the 
hugely diverse group that is idiopathic CRS. This finding was replicated in 2003 and 
postulated to be associated with the abnormally eosinophilic mucin seen in AFS. [38] This 
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was reflected in some in vitro work carried out on peripheral mononuclear blood cells 
(PMBCs). Exaggerated proliferative and cytokine responses were seen when PMBCs from 
CRS patients were exposed to various common or ubiquitous fungi, but the same was not 
observed in control cells. [39] Unfortunately, however, these results were not replicable. [40] 
Interest in fungi as the inciting agent for CRS has waned especially since large-scale trials 
have been unsuccessful in demonstrating any significant benefit with anti-fungal therapies in 
CRS populations versus healthy individuals. Neither reductions in objective or subjective 
disease severity scores nor any change in pro-inflammatory cytokine profiles were seen with 
amphotericin-B nasal lavages. [41, 42] Despite these findings fungi have not been entirely 
discarded in current CRS research. Abnormally heavy fungal colonisation is still associated 
with more severe disease and is considered to have an important role in promotion of Th-2 
responses typically seen in CRS. [23] 
 
1.2.4 The viral hypothesis and the role of interferons 
 
The role of viruses in the pathogenesis of CRS is uncertain. In some cases patients appear to 
develop CRS after exposure to viral URTIs. In others with pre-existing disease viral URTIs 
commonly exacerbate symptoms. Of these various respiratory viruses rhinovirus (RV) is the 
most prevalent, with coronavirus (CoV) and influenza also making significant contributions. 
[43] Historically however, it has been difficult even to characterise the exact viruses at play 
in the sinonasal microbiome. Persistence of respiratory viruses in the mucosa of CRS 
sufferers higher than that of the general population has been observed to a degree. [44, 45] 
Preliminary data have shown that this viral infection may hamper a subsequent immune 
response to bacterial nasal and paranasal sinus infection. [46] Theoretically this may disrupt 
the microbiome and aggravate, or indeed cause initial development of, the symptoms of the 
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disease. A reasonable amount is known regarding mechanisms underlying viral-bacterial co-
infection in the respiratory tract. It would appear viruses play a role in priming the mucosa 
for bacterial invasion (discussed further in “1.5 Viral-bacterial co-infection”). Why this may 
occur more frequently or more vigorously in CRS patients than in the general population is 
unknown. The culprit may be defective interferon (IFN) responses to viral infection in CRS, 
leading to prolonged and potentially more frequent and severe bacterial infections in that 
population. [47] 
 
IFNs are innate immune signalling proteins synthesised and expressed by almost all human 
cells in response to infection and/or autoimmune disease. There have been three types 
described in humans; type 1 (consisting largely of IFN-α and IFN-β, but also IFN-ε, IFN-
κ and IFN-ω), type 2 (IFN-γ) and type 3 (IFN-λ, of which there are four subtypes; IFN-λs 1-
4). IFN-λ1 is also known as IL-29, and IFN-λ2 and IFN-λ3 as IL-28A and IL-28B 
respectively. [48] They exert their downstream effects by binding to their receptors to induce 
expression of hundreds of different genes with different methods of modulating the immune 
response to the original pathogen (figure 1.2). In brief these include: 
• Promotion of apoptosis in diseased cells 
• Inhibition of viral protein synthesis 
• Induction of RNases that digest double-stranded viral DNA in order to limit 
replication 
• Induction of protein kinase, limiting viral replication and inducing apoptosis 
• Activation of the tumour suppressor gene p53, which induces apoptosis 
• Priming of neighbouring cells for early apoptosis on exposure to virus 
• Upregulation of the major histocompatibility complexes (MHC) classes I and II to 
allow increased recognition and killing of diseased cells 
25 
 
• Activation of macrophages and natural killer cells 
• Activation of numerous signalling cascades with ultimate antiviral and anti-
proliferative effects, including STAT, CRK and PI3K pathways 
 
Figure 1.2 Origin and downstream effects of virus-induced IFN expression. 
 
IFN receptors have been found to be IFN type-specific and largely ubiquitous for the type 1 
and 2 proteins, ie. the receptors are present in almost all human cell types and can be bound 
by any IFN molecule of the appropriate type. This is not true of the type 3 IFN-λs; their 
receptors (IFNLRs) are variably expressed (largely by epithelial immune cells) and bind with 
differing affinities to differing IFN-λ molecules. [49] All three IFN types have been shown to 
play a role in the innate immune response to viral infection, but none to a greater degree than 
IFN-λ. IFN-λ is emerging as more and more important in the early defences and clinical 
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outcomes of respiratory epithelium to its near-constant onslaught by respiratory viruses. As 
such it may have a role in the aetiopathogenesis of CRS. 
 
In vitro models have identified IFN-λ as a potentially more important contributor to viral 
respiratory infection than the other IFN types. BEAS-2B (a human bronchial epithelial 
carcinoma cell line), hBECs (primary human bronchial epithelial cells) and PMBCs have 
been infected with RV and assayed for IFN-α, IFN-β and IFN-λ. This resulted in a transient, 
early IFN-α rise, a late IFN-β rise, and a strong and persistent increase in IFN-λ in BEAS-2B. 
A similar pattern but at very low levels was seen in the hBECSs. All three of the investigated 
IFNs were strongly and persistently increased in the PBMCs. [50] RSV (respiratory syncytial 
virus) infected primary paediatric hBECs have shown an exclusive IFN-λ response, with no 
accompanying rise in type 1 IFNs. [51] This was supported by some work done with hNECs 
and the A549 cell line; when infected with RSV these mounted purely IFN-λ responses, and 
when treated with exogenous IFN-λ RSV replication was markedly suppressed. [52] 
Unfortunately these primary cells were harvested from allergic rhinitis patients, and so are 
perhaps subject to disordered inflammatory responses to invading pathogens/self already. 
Regardless these findings do add weight to the concept of IFN-λ being the first line of URT 
(upper respiratory tract) viral defence. In addition to this RSV has been postulated not only to 
induce IFN-λ preferentially, but to inhibit type 1 IFNs by the action of its NS1 and NS2 
genes. [53] PIV-3 (a virus highly restricted to airway epithelium,) when introduced to the 
Vero and BEAS-2B cell lines has consistently shown a marked increase in IFN-λ1 expression 
across human, bovine and dolphin viruses. These cell lines are not known to be particularly 
representative of normal human airway epithelium, but the results are in keeping with those 
investigating similar viruses. [54] Influenza is also known to induce IFN-λ expression. 
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Human and murine airway epithelial cell (AEC) cultures induce both IFN-λ and (to a lesser 
extent) IFN-β responses. [55] 
 
Animal models have drawn similar conclusions identifying IFN-λ as more active in viral 
respiratory infection than the other IFN subtypes. Influenza A-infected either wild type (WT), 
type 1 IFN-deficient or STAT2-deficient mice have displayed greater expression of IFN-λ 
than IFN-α/IFN-β in both the upper and lower airways. [56] Similarly intranasal IFN-λ 
administration has been shown to protect type 1 IFN-deficient mice from influenza infection 
[57] and to reduce influenza viral load and severity of disease in WT mice. [58] Conversely, 
IFN-α treatment in WT influenza-infected mice does restrict viral replication but worsens 
symptoms and increases proinflammatory cytokine secretion, innate immune cell recruitment 
and epithelial cell death. Similar findings have been made in influenza-infected primary 
human epithelial cells and PMBCs. MPV (metapneumovirus) has also been investigated in 
this context. This virus was found to induce all four IFN-λ ligands in mice and in the A549 
cell line, and to a greater degree than that induced by RSV in those same mice and cells. [59]. 
SARS-CoV-1 has been investigated in a similar manner using STAT1-deficient mice, type 1 
IFN-deficient mice, type 1 and 2 IFN-deficient mice (double knock-out (DKO) mice) and 
WT mice. STAT1-deficient mice are known to be more susceptible to SARS-CoV-1 and the 
DKO mice were able to mount only a type 3 IFN response. STAT1-deficient and the DKO 
mice both had similar peak viral titres and kinetics of viral clearance but developed much 
higher peak viral titres than their WT counterparts. The DKO mice remained clinically well, 
but STAT1-deficient mice developed liver pathology and eventually succumbed to 
neurological disease. From this the investigators concluded the STAT1-deficient mice’s 
inability to control SARS-CoV-1 infection was due to impaired IFN type 1 and 3 signalling, 
but failure to control systemic viral spread was due to unrelated defects in the STAT1-
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deficient mice. [60] Another comparative study used the DKO mice, type 1 IFN-deficient 
mice and type 3 IFN-deficient mice. These mice were infected with either SARS-CoV-1, 
influenza A, RSV or MPV. The investigators found that regardless of viral species there was 
greater pathogenicity, a worse clinical picture and higher replication titres in the lungs of the 
DKO mice than those lacking one IFN type only. They thus concluded both are important in 
respiratory tract defence to viral pathogens. [61] 
 
IFN-β has also received specific attention in the literature. This has been largely focused on 
RV and its role in chronic inflammatory disease of the lower airways, but elements of this 
work might be hypothesised to reflect the state of play in CRS. 85% of asthma exacerbations 
are triggered by viruses, RV being the most significant contributor. [62] An excellent paper 
written by a group of English researchers in 2005 aimed to investigate the mechanism of 
observed increased RV susceptibility in asthmatics. hBECs were sampled by brushing at 
bronchoscopy. Cells were taken from 24 asthmatics and 10 controls. Cell cultures were then 
infected with either RV16, RV1B, medium alone, or UV-inactivated RV16. The authors 
found a 50 versus 7-fold increase in viral RNA in the supernatants of asthmatic versus control 
cells. ICAM-1 (intercellular adhesion molecule 1) is the cellular receptor for the major RV 
group, including RV16. ICAM-1 expression was upregulated in all groups, but much more so 
in asthmatics. LDLR is the cellular receptor for the minor RV group, including RV1B, but its 
expression was not investigated in this study. Early impairment of IFN-β mRNA and protein 
expression in cellular supernatants was found in both groups, but again far more in the 
asthmatics. Asthmatic cells were then treated with exogenous IFN-β, which induced 
apoptosis and reduced viral replication. This identifies IFN-β as another potential treatment 
or preventative target in virus-induced asthmatic exacerbations, and as such may have a role 




Both IFN-λ and IFN-β appear to be negatively affected by a Th2-skewed inflammatory 
profile. This is interesting considering many CRS sufferers show a Th2 preponderance with 
induction of pro-inflammatory IL-4 and IL-13 cytokines. Th2 inflammation has been 
associated with impaired immunity to RV in ex vivo hBECs, [64] and so has been postulated 
as a potential mechanism behind this increased susceptibility to viral infection. BEAS-2B, 
hBECs from normal individuals and hNECs (primary human nasal epithelial cells) from 
patients with allergic rhinitis have been pre-treated with IL-3 and -14 to simulate Th2 
inflammation. Cell cultures then exposed to RV produced significantly less IFN-β and IFN-λ 
and allowed significantly more RV replication. [65] This is notable as it may be part of the 
mechanism underpinning a defective IFN response to viral infection in CRS. 
 
A study from South Korea attempted to unite this work on IFN in the respiratory tract and 
CRS. This paper sparked the initial interest demonstrated in this thesis in the IFNs themselves 
as the potential culprit allowing more frequent or vigorous viral infections in CRS. The 
investigators took IT hNECs from 10 CRSwNP patients, 3 CRSsNP patients and 14 patients 
deemed controls (turbinectomy patients suffering from chronic hypertrophic rhinitis). Cells 
were grown in submerged culture and exposed to RV16 or phosphate-buffered saline as a 
control. They found a slightly delayed reduction in viral titre and a similarly slight reduction 
in IFN-β expression in the CRS patients versus control (cytokine profiling was limited to IL-
6 and IL-8 and was not significantly different between the groups). From this it was 
suggested that hNECs display a slightly impaired response to RV infection, but not to the 
marked degree seen in hBECs, and so perhaps they employ other methods of viral clearance 
not seen in the lower airways. However, the culture model used (undifferentiated, submerged 
hNECs rather than the perhaps more relevant ALI model), the small sample size, and the 
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degree of chronic inflammation likely present even in the control patients do cast some doubt. 
Additionally, the IFN-λ response was not explored. [47] 
 
Although they are not classically associated with type 3 IFN responses some bacterial 
infections have also been investigated in this light. Of particular interest to the sinuses S. 
aureus and P. aeruginosa-infected type 1 IFN-deficient mice (therefore mounting a 
heightened type 3 response to the bacteria) have been found to exhibit less pathology without 
any changes in the composition of their respiratory cellular infiltrates. [66] WT mice also 
infected with S. aureus have been found to mount a type 1 IFN response, at least in part due 
to protein A expression by the bacteria inducing IFN-β, JAK-STAT signalling and IL-6 
production. Type 1 IFN-deficient mice were also infected in the same study and thus were 
protected from the bacteria, presumably because of their inability to respond to it. [67] Being 
a largely bacterial disease this finding is intriguing in the case of CRS; might IFN 
supplementation improve response not just to viral infection, but to bacterial infection also, 
independent of its antiviral effects? 
 
There exists also the hypothesis that respiratory viruses might persist in the sinuses of CRS 
patients longer than in healthy individuals, and that this may be part of the mechanism behind 
the viral hypothesis of CRS. Many DNA viruses of the URT (in particular the Herpesviridae) 
are known to persist in the respiratory mucosa for almost a lifetime. The mechanisms for this 
vary and many focus on episomal latency or insertion of viral DNA into the host cell genome. 
As such many of these are irrelevant to the more common RNA viruses of the URT, but a 
recent study by Oldham et al. explored a newer mechanism of respiratory viral latency in 
some depth. Cellular immunity against viral infections requires antigen presentation by MHC 
class 1 molecules; antigen peptides enter the host cell, are transported to the endoplasmic 
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reticulum (ER) by the transporter associated with antigen processing (TAP), are loaded onto 
the MHC1 by the peptide-loading complex (PLC), and then brought to the cell surface, thus 
presenting the processed antigen peptides to the immune system. It can then be recognised by 
cytotoxic CD8+ T cells, which in turn programme the cell for apoptosis. There are many 
proposed mechanisms of viral evasion of the immune system exerting their effects on any of 
these steps, but this study investigated the possibility for TAP defects to keep antigens hidden 
from T cells, resulting in immunodeficiency. Five viral proteins that inhibit TAP were 
identified from the herpes and cowpox families, the most important being ICP47. This is 
produced by herpes simplex viruses (HSV) 1 and 2 and blocks TAP activity, reducing MHC1 
surface expression, in turn evading recognition by the immune system and resulting in the 
lifelong infection characteristic of these viruses.  [68] There are many human viruses capable 
of similar latency, if by different mechanisms (for example hepatitis C, HIV and some of the 
other Herpesviridae) and so it is not unreasonable to suspect that upper respiratory viruses 
may be capable of similar evasion of the immune system. This would be of significant 
interest to the viral hypothesis of CRS; are the common cold viruses not just more prevalent 
in CRS populations, but are they (and thus their deleterious effects on the immune response 











1.3 Disease severity in chronic rhinosinusitis 
 
CRS severity can be gauged subjectively using various symptom-based patient 
questionnaires. These include the SNOT-22 (Sino-Nasal Outcome Test 22) questionnaire, the 
ADSS (Adelaide Disease Severity Score) and the Visual Analogue Score (VAS). Objectively, 
severity can be measured using computed tomography (CT) and the Lund MacKay score 
(LMS), or endoscopically using the Lund Kennedy score (LKS). 
 
1.3.1 Subjective measurement 
 
Multiple quality of life (QoL) questionnaires have been established for assessment of 
symptom severity and to measure efficacy of interventions in CRS. Most address rhinological 
symptoms, their effect on the patient’s activities of daily living (ADLs), the emotional impact 
of the disease, or a combination of such. Most also attempt to correlate with objective disease 
measurement tools and disease outcomes. Questionnaires include the SNOT -16, -20 or -22, 
ADSS, 31-Item Rhinosinusitis Outcome Measure (RSOM-31), VAS, Rhinosinusitis 
Disability Scale (RSDI), Sinusitis Control Test (SCT), Questionnaire of Olfactory Disorders 
(QOD) and Chronic Sinusitis Survey (CSS). The SNOT-22 (figure 1.3, modified from the 
SNOT-20) has been the most widely accepted of these, and was validated in 2009 by Hopkins 
et al. [69] The SNOT-22 has faced criticism for its length and lack of specificity in terms of 
rhinological symptoms. This led to the development of the shorter and more directed ADSS 
in 2013 (figure 1.4). [70] Multiple versions of the VAS (figure 1.5) exist; it has also received 
criticism for its difficulty to complete; overwhelmed with choice, patients are often confused 
as to which point best suits them. It also requires precise post-questionnaire distance 
measurement, and interpretation of the resulting wide range of raw scores has been 
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problematic. [71] A recent systematic review deemed the SNOT-22, QOD and SCT as the 
most valid available tools. [72] However, these can all be quite lengthy and thus difficult for 
patients to complete. This is largely due to inclusion of details of emotional well-being, 
generalised systemic symptoms and patient expectations and preferences, and so the choice 
of questionnaire must take this into account. 
 
































1.3.2 Objective measurement 
 
Multiple scoring tools have been developed for objectively assessing CRS severity and again 
no consensus exists as to their optimal use. The most popular are likely the LMS and LKS. 
 
There do exist other radiological scoring systems for sinus disease besides the LMS. These 
include the systems suggested by Jorgensen et al, [74] Weber et al. [75] and Newman et al. 
[76]) Historically however, the LMS (figure 1.6) [77] has been the most widely employed. It 
uses CT imaging of the sinuses and scores the maxillary, anterior ethmoid, posterior ethmoid, 
sphenoid and frontal sinuses 0-2 on each side. 0 indicates no disease, 1 indicates partial 
opacification and 2 indicates complete opacification. The ostiomeatal unit (OMU) is scored 
either 0 or 2 on each side (0 indicating no obstruction, 2 indicating obstruction). This gives a 
total score out of 24. Its popularity is likely due to a combination of its simplicity, [78] 
reproducibility, [79] and high intra- and inter-observer agreement. [80] More recent work has 
exhibited its reliability when derived from radiologists’ reports in the absence of the images 
themselves. [81] The LMS, however, correlates poorly with symptom scores [78] and has 
received criticism for the simplicity of its scoring. There exists a significant difference 
between mild mucosal disease and severe disease that has not yet reached complete CT 





Figure 1.6 Lund MacKay scoring system (adapted from Lund and MacKay). [77] 
 
Existing endoscopic scores include the Perioperative Sinonasal Endoscopic (POSE) score 
(figure 1.7), the Discharge, Inflammation, Polyp (DIP) score (figure 1.8) and the LKS (figure 
1.9). The LKS, perhaps the most often used of these, is simple to undertake during a standard 
three-pass rigid nasal endoscopy. It scores polyps, oedema, discharge, crusting and scarring 
each from 0 to 2 on each side for a total score out of 20. It has not, however, been validated 
and has been reported to correspond minimally with subjective severity scoring systems. [82] 
The modified LKS (MLK, figure 1.10) excludes the scoring of scarring and crusting. Both 
elements are present largely in populations having already undergone functional endoscopic 
sinus surgery (FESS, the LKS being originally designed for post-operative use). Crusting is 
mitigated by the common use of sinus rinses both before and after surgery. As such a large 
proportion of patients who have not yet undergone surgery will have severe disease but score 
nothing for scarring and crusting. The POSE also includes scarring and requires scoring of 
specific sinuses. Correct scoring of many areas mentioned in the POSE requires complete 
visualisation which cannot be undertaken without FESS ie. despite being named the 
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Perioperative Sinonasal Endoscopic score it cannot be undertaken preoperatively. Psaltis et 
al. described the MLK score and compared it to other existing scoring systems. Patients 
undertook SNOT-22 and VAS pre- and post-operatively, while surgeons undertook the LKS, 
POSE, DIP score and MLK score intra-operatively. For analysis the SNOT-22 scores were 
subdivided into symptom-specific and generalised responses, and the VAS scores were 
subdivided into major and minor symptom groups. The DIP was found to correlate only 
weakly with total post-operative SNOT-22 scores. The LKS was found to correlate only 
weakly with post-operative symptom-specific SNOT-22 scores, with a modest correlation 
with total VAS scores. The POSE correlated only with post-operative symptom-specific 
SNOT-22 scores and major symptom VAS scores. The authors were unable to correlate the 
POSE with pre-operative questionnaires given the nature of this post-operative scoring 
system. The MLK was found to correlate positively both pre- and post-operatively with 
symptom-specific SNOT-22 and major symptom VAS scores. [83] As such the MLK may  
represent the most useful endoscopic scoring tool currently available. 
 
 






Figure 1.8 Discharge, Inflammation and Polyp scoring system (adapted from Durr et al.). 
[85] 
 
Figure 1.9. Lund Kennedy scoring system (adapted from Lund et al.). [86] 
 
 




1.4 Virology of the upper aerodigestive tract 
 
The human upper aerodigestive tract is a highly colonised area playing host to a myriad of 
viruses, bacteria, bacteriophage and other micro-organisms. Here discussed is a brief 
introduction to some of the more common viruses found in the sinonasal passages; 
adenovirus (AdV), influenza virus, coronavirus (CoV), parainfluenza virus (PIV), rhinovirus 
(RV), respiratory syncytial virus (RSV), metapneumovirus (MPV), bocavirus (BoV), 




AdVs (figure 1.11) are non-enveloped double-stranded DNA viruses largely causing febrile 
illnesses in children, URT syndromes and pneumonia. Less commonly the AdVs cause otitis 
media, conjunctivitis, gastroenteritis and cystitis. Transmission is via aerosol droplets, faecal-
oral, contaminated fomites or vertical. There are over 50 subtypes classified into groups A to 
F based on haemagglutination pattern. Groups B and C are associated with URT disease and 
are most prevalent. [87] Viral shedding usually occurs from the URT for three to five days, 
and from the eye and stool for more than two weeks. However this can persist for months in 
some cases. Diagnosis is largely by polymerase chain reaction (PCR). Paired serology taken 
during acute illness and in the following days to weeks can indicate recent infection, but 
circulating anti-adenoviral antibodies are seen in most individuals by the age of 10. [88] Thus 
serology has limited clinical application. The antiviral agent cidofovir can be used to combat 
AdV but is usually reserved for the immunocompromised and very severe disease. Infection 
control includes standard measures of patient cohorting, personal protective equipment (PPE) 




Some work done by a group of researchers in Germany in 1987 investigated the potential for 
AdV to persist long-term in human lymphoid tissue. Samples of tonsillar and adenoid tissue 
were taken and assessed for presence of AdV2 using in situ hybridisation and cell culture 
over a period of eight weeks. AdV2 is one of the most commonly isolated sub-species from 
the C-group of AdVs, along with types 1, 5 and 6, and in situ hybridisation was quite a novel 
technique for the time. During the period of culture the isolated primary cells were 
intermittently assessed for cytopathic effect (CPE), and AdV2 was successfully identified 
both in samples displaying and not displaying such. There was unfortunately no discussion of 
numbers of samples used, statistical analyses employed, and there was very little explanation 
of control samples. Despite this the results remain intriguing as to the possibility of truly 
latent (ie. insertion of viral genomic material into the native cellular genome, with only 
periodic expression of viral RNA) adenoviral infection in human tissues. [89] This may be 
relevant to CRS given its relapsing nature but has not been specifically investigated in the  
sinonasal tracts, or in CRS. 
 
 
Figure 1.11 Electron microscope image of adenovirus, reproduced with permission. [90] 
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1.4.2 Influenza virus 
 
Influenza viruses (figure 1.12), more commonly known as the flu, are enveloped RNA 
viruses of the family Orthomyxoviridae. Epidemics occur nearly every year, mainly in winter. 
Influenza is classified into groups A, B and C (with a recently proposed fourth D group) all 
characterised by the presence of two major surface glycoproteins. These are haemagglutinin 
(HA) and neuraminidase (NA). HA is involved in virus-target binding and viral entry into the 
cell, while NA mediates release of progeny virions after intracellular replication. The 
segmented nature of the influenza genome allows high reassortment rates in different virus 
particles infecting the same cell. This causes both major and minor changes in the envelope 
glycoproteins (termed antigenic shift and antigenic drift, respectively). These result in regular 
influenza outbreaks of varying sizes. Influenza classically causes both upper and lower 
respiratory tract (LRT) symptoms, but can be complicated by pneumonia, myositis and 
rhabdomyolysis, central nervous system disease (encephalopathy, meningitis, transverse 
myelitis and Guillain-Barre syndrome) and cardiovascular disease (ischaemic heart disease, 
myocarditis and pericarditis). Complications can also arise secondary to bacterial 
superinfection, such as bacterial pneumonia, acute sinusitis and otitis media. Complicated 
influenza can be especially problematic at extremes of age and in the immunocompromised. 
Viral shedding occurs 24 to 48 hours prior to symptom onset and can continue for up to 10 
days. NA inhibitors (zanamivir, oseltamivir and peramivir) reduce symptom duration by one 
to three days if initiated within 48 hours of onset. [91] These, however, are largely reserved 
for high risk populations. High risk populations include infants and the elderly, pregnant and 
post-partum women, the morbidly obese, patients with significant comorbidities, the 
immunocompromised, and any patients requiring hospitalisation for the sequelae of their 
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influenza infection. Again, preventative measures include patient cohorting or isolation, PPE 















CoVs are enveloped RNA viruses classified into four genera (α, β, γ, and δ) of which only 
two (α and β) contain the human CoVs. The human CoVs are 229E, NL63, HKU1, OC43 and 
the more recently discovered MERS, SARS-CoV-1 and SARS-CoV-2 (CoVID-19) strains. 
Many of the coronaviruses, like AdV, are almost ubiquitous, but like influenza cause 
respiratory illness largely in winter in temperate climates. Transmission is via contact with 
infected secretions or aerosolised droplets. CoVs cause URT symptoms and have been 
implicated in otitis media, pneumonia and inflammation of the lower airways. Given there is 
currently no treatment available diagnosis of CoV infection has limited clinical application 
beyond patient cohorting and PPE. 
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1.4.4 Parainfluenza virus 
 
Only distantly related to influenza, PIVs are enveloped RNA viruses of the family 
Paramyxoviridae (which also includes RSV and MPV). The virus is transmitted via 
aerosolised droplets or direct contact with infected secretions, and serotypes 1 to 4 have been 
identified. Prevalence is PIV3, 1, 2 and 4 in descending order. [94] PIV causes URT 
symptoms and is associated with pneumonia, exacerbations of chronic airways disease, otitis 
media, acute sinusitis, and meningitis, myocarditis and pericarditis. The latter three are rare 
occurrences. Again, the more severe sequelae are seen largely in extremes of age or in the 
immunocompromised. Diagnosis is also largely by PCR; serology is clinically impractical for 
similar reasons to those detailed for AdV. However without any available treatment 
modalities besides supportive care, laboratory-confirmed PIV infection is of little immediate 
clinical consequence.  
 
Of interest in the sinuses PIV has been associated with post-viral olfactory dysfunction 
(PVOD) after the common cold. Little investigation has been done into this particular 
association, but one study did show significant PIV3 presence in inferior turbinate (IT) 
scrapings in patients complaining of PVOD up to 12 months following reports of initial 
URTI. 88% of PVOD sufferers demonstrated PIV3 versus only 9% of control patients 
undergoing isolated septoplasty. Said initial cold, however, was not investigated to confirm 








A member of the picornavirus family, RV is a small, non-enveloped RNA virus that 
proliferates in the relatively cold environment of the nasopharynx (33 to 35°C). There are 
over a hundred human RVs and these are further classified into A, B or (the newest) C 
groups. Within the A and B groups there also exist major and minor RV types; these are 
based on the cellular receptors used by the virus when attaching and initiating infection in the 
host cell. ICAM-1 is used by the 89 major types, and LDLR is used by the 10 minor types. 
The receptor for the RVC group may be CDHR3, but this is unconfirmed. [96] Transmission 
is via aerosolised droplets, direct contact with infected secretions, or fomites. Of particular 
interest is RV’s ability to remain viable outside of the host for up to three hours. The 
incubation period is 24 to 72 hours, as is the case for most URT viruses. Infected cells exist in 
the host in patches, and nasopharyngeal RV shedding usually occurs for five to seven days. 
This corresponds to average duration of symptoms but can continue for up to three weeks. 
RV is a major culprit of symptoms associated with the common cold but is also responsible 
for exacerbations of chronic obstructive pulmonary disease (COPD) and asthma. It is also 
associated with a more severe clinical picture in infants, the elderly and the 
immunocompromised. There are currently no available treatments or vaccines, and there is 
little to no cross-protection amongst the many serotypes. 
 
RV has a known association with acute sinusitis; this has been well documented for decades, 
including by a group of American researchers. They recruited healthy volunteers and infected 
them with RV39. They then compared pre- and post-infection symptom scores, MRI 
evidence of development of sinus disease, nasal secretion volume and viral shedding in nasal 
lavages. Over half (18) of their volunteers were successfully infected with RV, but only four 
45 
 
of these developed any radiologically visible acute sinus changes. There were no significant 
differences in symptom scores between these four patients and those with persistently normal 
MRIs. Interestingly however the volume of the nasal secretions in these presumed acutely 
sinusitic participants increased five-fold. In this study the researchers did not, however, use 
any control patients with sham infections. Neither did they follow up the four patients 
displaying RV-induced sinus disease long-term to investigate the possibility of 
transformation into a chronic disease process. [97] 
 
1.4.6 Respiratory syncytial virus 
 
Another RNA virus of the Paramyxoviridae family is RSV. First isolated as the cause of a 
nosocomial outbreak of colds in chimpanzees in the mid-1950s, [98] RSV has both A and B 
subtypes. Both are usually present in outbreaks but the A subtypes generally cause more 
severe disease. RSV is almost ubiquitous by the age of two, and transmission is via direct 
contact with infected secretions, fomites or (less commonly) aerosol droplets. RSV, like RV, 
can survive for hours outside of the host. Incubation is somewhat longer than most URT 
viruses at four to six days. RSV causes both URT and LRT disease largely in infants and 
children. It is associated with significant apnoea in infants, conjunctivitis, and occasionally 
bacterial superinfection in the respiratory tract, urinary tract and central nervous system. Its 
tendency to induce asthma and recurrent wheeze in children has been particularly 
problematic. [99] Laboratory diagnosis, when required, is largely by PCR of nasopharyngeal 
secretions. Care is supportive, but there is some emerging evidence for ribavirin (a nucleoside 
analogue) in adults with RSV after haematopoietic cell transplant. [100] Palivizumab (a 
monoclonal antibody against the F glycoprotein of RSV) can be used for prevention in high-
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risk infants. Although multiple vaccines are in development none are currently commercially 
available. 
 
Some investigation into RSV and its action in chronically inflamed lower airways has been 
undertaken. This included two very similar studies comparing RSV infection in CF and 
healthy well-differentiated nasal, tracheobronchial and bronchiolar epithelial cells grown at 
air-liquid interface (ALI). As do many of the articles mentioned in this review of the 
literature, the investigators chose these cells as they can be grown into an organ culture 
closely mimicking the in vivo state of their parent cells. The ALI model allows the 
development of multilayered, pseudostratified, mucociliary tissue including basal support 
structures. The first of these studies investigated preferential infection sites. Despite direct 
inoculation of apical, basal and intermediate cell types, there was a clear predilection for the 
apical, ciliated cells across all three airway collection sites. The later of these two studies 
found that RSV caused no visible CPE in this ALI model up to three months after infection. 
This was in the absence of an adaptive immune response, as is the case in the ALI 
environment. [101] This suggests the pathogenicity of RSV may depend largely on said 
adaptive immunity, rather than direct CPE. Conversely, the earlier study found demonstrable 
CPE on light microscopy as early as two hours post-infection. [102] The author of this review 
of the literature cannot discern any obvious differences in the two articles that would account 
for this, but would suggest that a mucosal explant model, which would retain at least some of 
its immune capabilities and be vastly simpler to generate, would be another acceptable choice 







The third member of the Paramyxoviridae family pertinent to this thesis (along with PIV and 
RSV) is MPV. Genetically similar to RSV, MPV is an enveloped RNA virus which, also like 
RSV, has A and B subtypes with two clades in each. These are termed A1, A2, B1 and B2. 
The virus was first isolated in 2001 so formal transmission and shedding kinetics studies have 
not yet been completed. It would appear most children have been infected by the age of five. 
[103] MPV causes URT disease, bronchiolitis and exacerbations of asthma and pneumonia 
largely in the very young or very old. It also has a possible association with encephalitis 
[104] and exacerbations of COPD. [105] RT-PCR (reverse transcription polymerase chain 
reaction) is well-developed for MPV detection, but again, current treatment is supportive only 
and so laboratory diagnosis is useful largely for infection control. Vaccines are under 
development, but none are near licensure.  
 
A group of researchers in Brisbane in 2014 highlighted the lack of investigation into chronic 
airways diseases and viruses other than RV. As such they investigated the innate immune 
response of children not yet diagnosed but at risk of asthma to RSV and MPV. Primary nasal 
and tracheal epithelial cells were taken to compare the upper and lower airways. These cells 
were cultured, transfected, and assessed for viral replication and inflammatory cytokine 
production. Of particular interest, again, were IFN-β and IFN-λ. As stated previously, 
deficiency in these has been identified in severely asthmatic adults. The researchers sought to 
determine if this deficiency precedes and therefore may have a role in development of 
asthma, or if it is acquired, perhaps by viral infection itself in susceptible individuals. Their 
main finding was that RSV-infected tracheal epithelial cells produced less IFN-β versus 
control. Interestingly none of the other three groups (RSV-infected hNECs, MPV-infected 
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tracheal cells, and MPV-infected nasal cells) showed any change in inflammatory cytokine 
production when compared with controls. All four groups, however, displayed significantly 
greater viral replication. This would suggest that higher viral loads are seen in atopy and 
wheeze (the study recruitment criteria) but the impaired anti-viral response is not IFN-
mediated, and an IFN deficiency does not precede the development of asthma in 
wheezy/atopic children. Participants for this work were recruited at time of elective 
otolaryngologic surgery, largely for adenotonsillectomy. This group are themselves subject to 
chronic airways inflammation, and so even in the absence of asthmatic risk factors are 
perhaps not as “healthy”, (and therefore perhaps not as capable of mounting a normal innate 




Human BoV is a parvovirus first identified in Sweden in 2005 [107] and causes largely LRT 
illness in children, especially under the age of two. It is most prevalent during winter and is 
commonly found in the presence of additional respiratory viruses. It has been associated 
loosely with human gastrointestinal disease and has been detected in serum. [108, 109] Being 
a relatively new respiratory pathogen understanding of its role in causality of clinically 
apparent disease is limited. As yet there are no treatment strategies available bar supportive 




EnV is a small RNA virus of the picornavirus family closely related to RV. EnV causes 
disease throughout the year in patients of all ages, but most often in small children. 
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Designations A to J of EnV have been identified and transmission is faecal-oral. Apart from 
both URT and LRT disease EnVs are classically associated with poliomyelitis, as well as 
exanthemas, meningitis, encephalitis, conjunctivitis, pleurodynia and peri/myocarditis. Most 
EnV infections are self-limiting and do not require specific treatment outside of supportive 
care. In severe cases intravenous immunoglobulin has been used to anecdotal benefit in EnV-
encephalomyelitis. [110] The capsid inhibitor pleconaril has shown some favourable results 
in neonatal populations. [111] Administration of the poliovirus vaccine is currently 
undertaken worldwide as part of the WHO plan for eradiation, which has been largely 




The Herpesviridae are a large family of DNA viruses, nine of which are known to infect 
humans. Among these are HSV (herpes simplex virus), CMV (cytomegalovirus), EBV 
(Epstein Barr virus), VZV (varicella zoster virus), HHV6 (human herpes virus 6) and HPV 
(human papilloma virus). Herpesviridae are rampant in humans; up to 90% of adults have 
been infected with at least one of HSV, CMV, EBV and VZV, as evidenced by persistent 
latent infection in many. [109] There have been multiple mechanisms postulated to result in 
the lifelong infection seen in these viruses. The most commonly held theories include the 
encoding of a homologue to IL-10 [112] and downregulation of the MHC class 1 on the 
surface of infected cells. [113] The former inhibits synthesis of pro-inflammatory cytokines 
and the latter prevents T cell recognition of non-self. The clinical manifestations of 
Herpesviridae infection are varied and are summarised in table 1.1. The majority of these are 
self-limiting and require no treatment in immunocompetent individuals, but for severe cases, 
in extremes of age and in the immunocompromised there are a number of antiviral options. 
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These are also summarised in table 1.1, but evidence for most of these is minimal. 
Vaccination schedules are well established for VZV and HPV primary prevention, and EBV 
vaccination is in the animal trial stage. Currently no vaccines available for any of the 
Herpesviridae have a mitigating effect on latent infection. 
 
 
Viral species Possible clinical manifestations Systemic antivirals available 
HSV Cutaneous lesions, encephalitis, 
meningitis, hepatitis, pneumonitis, 




EBV Infectious mononucleosis, lymphoma, 
stomach/nasopharyngeal carcinoma, 
associated with multiple sclerosis 
Acyclovir 
CMV Mononucleosis, gastrointestinal upset, 
encephalitis, Guillain-Barré syndrome, 












VZV Chicken pox, shingles, encephalitis, 









1.5 Viral-bacterial coinfection 
 
It is historically very well documented that viruses increase susceptibility to secondary 
bacterial infection. Given the extensive implication of bacteria in the aetiopathogenesis of 
CRS (see section 1.2.2), any event that might allow greater bacterial colonisation and 
infection (an URTI for example) would be of significant interest. Research into viral-bacterial 
co-infection, however, has largely focused on the LRT. This is largely due to the significant 
mortality and morbidity associated with diseases such as asthma and COPD. Research is also 
plagued with difficulty when attempting to identify the exact viral pathogens involved in this 
association. Investigation into the mechanisms behind viral-bacterial co-infection in the LRT 
has elucidated a number of biological changes likely responsible for the clinically observed 
phenomenon of increased secondary bacterial infection susceptibility. These may be 
somewhat applicable to the URT. These changes can be grouped into factors affecting 
epithelial barrier function, those affecting bacterial binding, those influencing innate and 
adaptive immunity, changes in the lower respiratory microenvironment and direct 
interactions between the viruses and bacteria themselves. [114] 
 
1.5.1 Interactions in the lower respiratory tract 
 
Influenza in particular has been repeatedly linked to bacterial infection in the LRT, often S. 
pneumoniae. Significantly increased rates of bacterial pneumonia during influenza outbreaks 
have been reported for decades, but isolation of the preceding virus in human populations is 
difficult given the generally rapid clearance of such pathogens from the airways. [115, 116] 
Perhaps the most infamous example of this synergistic relationship is the Spanish flu 
outbreak of 1918 and 1919. This was the largest and most devastating influenza pandemic of 
the 20th century. The morbidity and mortality it caused are believed to have resulted largely 
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from complications of bacterial superinfection (mainly with S. pneumoniae and S. aureus). 
[115] Influenza has also been linked with bacterial infections outside of the respiratory tract. 
Parallel outbreaks of influenza and meningococcal infection in the UK in 1989 were 
investigated with matched peri- and post-morbid virus serology and compared with healthy 
age-matched controls. Significant correlation was found between influenza A and Neisseria 
meningitidis (N. meningitidis) infection. [117] The authors of this study postulated this to 
represent either early virus-driven nasopharyngeal mucosal injury allowing greater bacterial 
adherence and penetrance, or a more central mechanism involving generalised virus-driven 
immunosuppression. 
 
1.5.2 Effects on epithelial barrier function 
 
Respiratory viruses cause increased mucus production in order to eliminate said virus, as 
indeed do any pathogens of the respiratory tract. This, however, can be counterproductive. 
Excessive mucus production is associated with obstruction and reduced mucociliary 
clearance, allowing further colonisation and infection by additional potential pathogens. [118] 
Viruses can also reduce ciliary beat frequency, [119] cause ciliary dyskinesia [120] and 
reduce numbers of ciliated cells. [102] They can cause epithelial cell death resulting in large-
scale physical disruption to the epithelial barrier. [121] On a smaller scale they can induce 







1.5.3 Effects on bacterial binding 
 
Particular host receptors are upregulated by particular viral infections, and some of these host 
cell surface molecules can also act as binding sites for bacteria. ICAM-1 and fibronectin, both 
native cell surface receptors, are upregulated in influenza infection. Both have been shown to 
allow increased binding of H. influenzae, S. aureus and S. pneumoniae. [125] Influenza, RV, 
RSV and PIV have all been shown to induce platelet activating factor receptor (PAFR) 
expression in infected cells. This allows greater pneumococcal binding in vitro. [126-128] 
Unfortunately this result has not been replicated in vivo. In a mouse model of influenza PAFR 
blockage has effected no change in mortality or disease severity after bacterial superinfection. 
[129, 130] This does not necessarily suggest that PAFR upregulation has no role in this co-
infection, but perhaps that the mechanisms behind said co-infection are multifactorial in 
nature. 
 
Viral proteins expressed on the surface of host cells may also act as bacterial binding sites. 
The RSV attachment glycoprotein (G protein) can be bound by H. influenzae, [131] S. 
pneumoniae, [131, 132] and P. aeruginosa. [133] Influenza HA has been shown to bind to 
group A streptococci in a mouse model. [134] 
 
1.5.4 Effects on innate and adaptive immunity 
 
Common respiratory viruses can severely deplete local macrophage stores. This has been 
seen in a mouse model of influenza, in whom restoration of alveolar macrophage populations 
remedied an observed increased susceptibility to pneumococci. [135] This may also hamper 
neutrophil recruitment as this relies to some degree upon chemokine expression by local 
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immune cells. Indeed influenza and pneumococcal co-infection has been shown to induce 
direct neutrophil apoptosis. [136] Viruses can also impair the actions of natural killer cells, 
[137] they can interfere with antigen presenting cells, [138, 139] and impair T cell function. 
The lower airways of mice co-infected with influenza and S. pneumoniae produce less CD8+ 
and CD4+ T cells, less of their associated cytokines, and their Th-17 cells have been shown 
to produce less IL-17. [140-142] 
 
These viruses can also interfere with PRRs, including the TLRs. If cell PRRs encounter 
multiple pathogens over time, feedback mechanisms designed to prevent over-activation of 
adaptive immunity start to cause delayed or absent responses to further infection. This has 
been observed both in RV-infected pulmonary epithelial cells [143] and in RSV-infected 
mice [144] both faced with bacterial challenge. In the case of the mice, this poor response to 
further pathogens persisted for months after viral clearance. 
 
Suppression of innate immunity has been induced by the RSV G protein, [145] and non-
structural proteins of influenza and RSV. [146-148] The effects of this suppression on 
subsequent bacterial infection have not been elucidated, but it would be reasonable to 
hypothesise this would augment bacterial spread. [114] 
 
There may also be an element of virus-induced local antimicrobial peptide suppression at 
play. RV-infected COPD patients show much higher rates of secondary bacterial infections 
than non-infected COPD patients, and their sputum shows vastly reduced levels of the 
antimicrobial peptides secretory leucocyte protease inhibitor (SLPI) and elafin (another 




1.5.5 Effects on the respiratory microenvironment 
 
Viruses can change the availability of nutrients in the airways; for example influenza NA can 
cleave sialic acid from airway mucins. This can be metabolised by some pneumococci, and so 
it follows these bacteria may grow and divide more readily. [150] H. influenzae can also 
increase respiratory cell expression of ICAM-1, which influenza can then use as an 
attachment site. This leads to increased bacterial susceptibility and a heightened 
inflammatory response. [151] ICAM-1 over-expression also seen in RV infection has been 
postulated to be responsible for increased S. aureus internalisation by pneumocytes in the 
lower airways. [152] Virus-induced temperature change and availability of other intracellular 
micronutrients released on cell lysis can variably encourage biofilm formation, induce release 
of planktonic bacteria from biofilms, and accommodate their further spread in the respiratory 
tract. [153, 154] 
 
1.5.6 Direct viral-bacterial interactions 
 
There is some emerging evidence that apart from the indirect viral-bacterial interactions 
detailed previously, viruses and bacteria may directly interact in the lower airways. It is 
established that the RSV G protein can bind to pneumococci, which has been shown to 
change the bacterial transcriptome and render the bacteria more virulent. [155] There is some 
evidence that RSV may act as a direct coupling agent between epithelial cells and P. 
aeruginosa, however this work was undertaken in AEC lines only. [133] Influenza NA can 
alter the structure of some meningococcal capsules, leaving them with an enhanced ability to 
adhere to epithelium. [156]  
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1.5.7 Interactions in the upper respiratory tract 
 
Extensive investigation into viral-bacterial interactions in the LRT has been undertaken. 
There is a wealth of evidence that such an interaction is also likely in the URT; influenza has 
been consistently linked to acute bacterial sinusitis [157] and to otitis media in up to 40% of 
children infected with the virus. [158] Despite this the URT (and in particular the sinonasal 
passages) has not received attention equal to its lower counterpart. 
 
A South Korean group took IT hNECs grown at ALI and investigated components of the 
cells’ TJs and AJs after infection with RV. Expression of both was reduced compared to 
control non-infected cells. [159] This was supported by some work in Japan in 2011 using 
what appeared to be a similar protocol but with RSV in place of RV, however this was a very 
small study with very little explanation of methodology in the publication. [160] This has 
been extrapolated to some investigation into subsequent bacterial adherence in virus-infected 
tissues. A group in Japan infected primary tracheal epithelial cells with RV or RSV and 
super-infected these with S. pneumoniae. They found significantly increased bacterial 
adherence in the presence of both viruses. [127] The same South Korean group grew hNECs 
at ALI, infected these with RV, super-infected with either S. aureus, S. pneumoniae or H. 
influenzae. They then assessed expression of relevant host-cell adhesion molecules. They 
found there was significantly increased adhesion of all bacteria to the virus-infected cells. 
[46] The previously discussed link between influenza and meningococci (see section 1.5.1) 
has also been investigated in the upper airways. 19 nasopharyngeal mucosal explants were 
taken from the ITs of patients with nonallergic nasal obstruction, infected with influenza B or 
PBS as a control, and then with group B N. meningitidis. Pre-innoculation with influenza had 
no influence on bacterial infection when compared with control explants. [161] However, 
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influenza B is classically less virulent than the A subtype. Additionally only one strain of 
influenza and N. meningitidis each were investigated, and the influenza B was not strictly 
WT, being initially isolated in 1979 well before this study in 1999. 
 
Animal models of viral rhinosinusitis have been difficult to establish, and as such results have 
been mixed. Some animal work has been done to elucidate the effects of different influenza 
subtypes on subsequent bacterial infection. In a ferret model 90% of subjects pre-inoculated 
with H3N2 (a classically more virulent strain of influenza) developed clinical and 
microbiological S. pneumoniae infection in the form of sinusitis or otitis media. In contrast 
only 10% of subjects pre-inoculated with the classically less-virulent H1N1 or influenza B 
developed such infections. [162] Sendai virus is a highly pathogenic murine respiratory virus 
that can be used to mimic many aspects of RV infection seen in humans. These aspects 
include clearance of acute infection within ten days but persistence of T-suppressor and T-
regulatory cells and airway hyperresponsiveness long after said clearance. The mouse model 
of Sendai virus does not, however, display the eosinophilia so characteristic of most virally-
exacerbated CRS seen in humans. [163] 
 
Much like many other respiratory viruses, AdV has long been suspected to correlate with 
increased respiratory bacterial infections. A Swedish group in 1994 investigated the 
possibility of increased bacterial adherence to respiratory epithelial cells pre-infected with 
AdV. They found increased adherence of multiple S. pneumoniae strains in both the A549 
cell line and hNECs. Conversely, no change in bacterial adherence was found when the 
streptococci were substituted for H. influenzae. This is perhaps not unexpected in the A549 
cells; these originate from alveolar basal epithelial cells, and H. influenzae is known to infect 




RSV has been identified as a primer of both the upper and lower airways to secondary 
bacterial infection and allergic responses. As such, RSV may be of particular note when 
investigating the response of a chronically inflamed sinonasal tract to viral infection. Hament 
et al. compared adherence of various strains of S. pneumoniae to respiratory epithelial cell 
monolayers infected with RSVB. The investigators found a two- to ten-fold increase in 
bacterial adherence to the cells pre-infected with virus versus control, even though this varied 
somewhat amongst the bacterial serotypes. The host cells used were from two human 
carcinomatous cell lines (HEp-2 and A549). These two, along with most other respiratory 
epithelial cell lines, are widely accepted as poor mimickers of true in vivo cell behaviour. 
[165] In perhaps a more representative model, Das et al. harvested well-differentiated healthy 
hNECs from turbinectomy patients. These were transfected with RSV or control media in an 
attempt to induce this “priming” of the airways. Subsequently the pro-inflammatory cytokine 
tumour necrosis factor α (TNF-α) or a control compound were added, and the resulting 
cytokine profile was analysed. They found significantly elevated levels of IL-6, IL-8 and 
RANTES in RSV infection alone, and an even greater elevation of these with the addition of 
TNF-α to RSV-infected cells. In order to aid analysis the researchers used a green fluorescent 
protein-expressing RSV from RSV strain A2. There was little discussion of the similarity of 
this recombinant virus to its WT parent, so there could perhaps be some question regarding 
the in vivo relevance of these results. However, the over-arching implication of RSV in the 
induction of innate immune hyper-responsiveness remains compelling, and further 
experiments are needed to validate this in a diseased (eg. CRS) model. [166] 
 
Supportive work in the same vein has been done in Japan, investigating the cytokine profile 
and mechanistic interactions between RSV and in vitro upper AECs. Human telomerase 
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reverse-transcriptase-infected hNECs (hTeRT, giving the cells an extended lifespan) from 
hypertrophic rhinitis or CRS patients were infected with RSV. This induced pro-
inflammatory cytokines IL-8 and TNF-α itself. During this same study analysis of TJ protein 
expression was undertaken. Interestingly this was markedly increased in the infected cells. 
This increase in TJ expression also appeared to correlate with increased RSV budding from 
the apical cell surfaces. This is an intriguing finding as it does not correlate with current 
theories of viral disturbance of the epithelial barrier (ie. TJ disruption). The use of hTeRT-
treated hNECs has been somewhat validated in this and previous studies, [167, 168] but 



















1.6 Viral collection and processing methods 
 
Traditional viral sampling is taken from the inferior nasal septum and anterior nasal floor. 
These are easily accessible in the primary care setting (ie. endoscopic equipment and 
expertise are not required) and cause patients little discomfort. The posterior nasopharyngeal 
wall has been recommended historically, but endoscopic confirmation of access would be 
required. No evidence exists however, for any of these three sites over each other or indeed 
any other location in the sinonasal passages. Additionally the inferior nasal septum, anterior 
nasal floor and posterior nasopharyngeal wall are relatively close to airborne pathogens and 
therefore risk of contamination. They are relatively distant from the sinuses and may be 
subject to pooling of potentially contaminating secretions. Secretions often containing non-
replicating, extra-cellular, non-pathogenic virus. This is particularly pertinent to the anterior 
nasal floor.  
 
Viral collection techniques are another point of interest. Methods investigated in the literature 
include nasal washes, aspirates, brushings and traditional viral swabs [44, 45, 170-180]. 
Heikkinen et al. looked at viral swabs and nasal aspirates in the detection of influenza in 
children and found no statistically significant difference between the two. [181] Spiridakou et 
al. compared viral swabs, nasal aspirates, washes and brushings and their ability to sample a 
range of common URT viruses. The only significant difference found was in detection of RV 
with brushes and washes. RV detection was slightly higher in the washes, however the 
brushing was taken after all three other samples had already been harvested. As such much of 
the epithelial, virus-containing layer may have already been removed. In addition to this the 
washes could well be contaminated by ambient, non-replicating, non-pathogenic virus either 




An additional concern when sampling respiratory viruses is ensuring adequate cellular 
collection. Clinically relevant, actively replicating URT viruses are intra-cellular and have 
been shown largely to reside in the upper epithelial layers of respiratory mucosa. [118] 
Traditional viral sampling brushes are smaller, softer and more flexible than cell sampling 
brushes. This is more comfortable for the conscious patient and less traumatic to the mucosa, 
but again risks sampling largely mucosal secretions and not the cells in which the viruses 
reside. [182] Cytology brushes are larger and more rigid. It follows that these cause more 
discomfort and trauma, and if sampling from specific, more posterior areas in the sinonasal 
passages is required their size means these samples may be contaminated with cells from 
areas more anterior during insertion and removal. However, they have the significant 
advantage of increased cellular sampling yield. [183] 
 
Viruses, being obligate intracellular pathogens, are considerably more difficult to isolate and 
identify than bacteria. As such the arrival of nucleic acid amplification tests (NAATs) in the 
late 1980s has revolutionised viral detection methods. Prior to this respiratory viral pathogens 
were found either by cell culture in amenable cell lines or by antigen detection. Cell culture is 
a lengthy process and so is largely irrelevant in a clinical sense; by the time virus is grown 
and identified, the patient will have either recovered or succumbed. It also requires viable 
viral samples and so the processing laboratory must be nearby, and requires experienced 
interpretation of CPE. Many viruses will cause specific CPE in specific cell types, but this is 
not universal. Additionally, some common viruses do not grow well in cell culture, or do not 
do so at all. Antigen detection is a much faster, more clinically relevant method. 
Unfortunately it is also poorly sensitive and requires the existence of said antigens, which is 
unfortunately not the case for some very common viruses, RV and CoV for example. NAATs 
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are not without their drawbacks; they can detect virus in asymptomatic patients which can 
complicate interpretation. They can also be more expensive than the methods detailed above, 
and the presence of sequence variants may give false negatives. Sequence variants are 
especially prevalent in largely-RNA URT viruses. However, NAATs amplify even tiny 
amounts of viral nucleic acid to a readily detectable level, they are highly sensitive even 
when used on a non-viable sample, and they are rapid. This allows prompt patient treatment 
and cohorting. For these reasons most of this literature review will focus on studies 
employing NAATs (largely PCR) in their viral detection, as indeed will the work undertaken 


















1.7 Viruses and chronic rhinosinusitis 
 
Most research into the microbial influences on CRS has focused on the role of bacteria rather 
than viruses. This is partly due to the more common isolation of bacteria from CRS patients, 
as well as their ease of study. With this said, most patients with CRS do recollect a viral 
illness preceding the development of sinus symptoms, suggesting that viral infection may 
play an important role in the initiation of the inflammatory process. Although most virome 
studies of the upper airway to date have been population-based rather than disease-specific, 
there have been a few studies examining the prevalence of certain viruses in CRS cohorts.  
 
1.7.1 Conventional URTI-causing viruses and CRS 
 
Table 1.2 summarises the viral CRS studies that have been performed, including their 
methodology and salient findings. 
 
In 2006, Jang et al. isolated RV in IT scrapings of 21% of CRS patients and found RV to be 
completely absent in control patients. This prompted them to hypothesise that RV may be 
important in the aetiopathogenesis of CRS. This study did suffer from numerous limitations 
however, including small sample size, the absence of a truly healthy control group, seasonal 
sampling bias and the absence of polyps in the CRS cohort. Furthermore the possibility that 
the IT may not truly represent the paranasal sinuses in terms of viral burden must also be 
mentioned. [44] These limitations may explain why a follow-up mucosal explant model by 
Wang et al. failed to demonstrate any increase in RV susceptibility between CRS polyp tissue 




A later, larger study by Cho et al. sought to address many of the above deficiencies. In their 
study they examined nasal lavage and IT scrapings from CRS patients with and without 
polyps, compared to a more appropriate control group of patients undergoing tonsillectomy 
or thyroidectomy. Unlike the Jang et al. study they did not limit their assay to RV alone and 
instead screened for a large number of common viruses using PCR. They found 50.5% of 
CRS and 28% of control nasal lavages positive for one or more viruses, and 71% of CRS and 
30% of control scrapings positive for one or more viruses. However, given their collection 
methods, again it could be questioned how representative their samples were of the actual 
sinuses of these patients. [45] A similar study was done in China during winter comparing 
viral presence in MM scrapings of CRS patients with and without polyps as well as controls. 
They found similarly high rates of viral detection in all groups. Unfortunately the set of 
viruses for which they searched was comparatively small, only encompassing RV, RSV, 
influenza, PIV and CoV. [170] Similar work was done in Pittsburgh in the USA over the 
course of a year. This again used MM scrapings but with the addition of anterior ethmoid 
scrapings. All controls were negative for viruses while 20% of CRSsNP and 80% of 
CRSwNP were positive. Unfortunately the sample size was so small (32 patients) that the 
results are not compelling. [171] A group in New Zealand took ethmoid or sphenoid mucosal 
samples (no further details were given regarding the nature of these) from only 13 CRS 
patients and 2 healthy controls during summer and autumn. These were assessed for a wide 
array of viruses, including some not uniformly addressed in the aforementioned studies (BoV, 
CMV, HHV6 and EBV). They did not find any conventional viruses in any of the samples 
but did identify low titre HHV6 and EBV in the CRS patients only. The authors themselves 
identified their sample size and timing of sample collection as significant pitfalls in their 
work. This is especially true of their controls, numbering only two. [172] Many conventional 
URTI-causing viruses reside largely in the epithelial layer. As such it could be postulated that 
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the whole mucosal samples used in this study might not give the high virus titres seen in 
some of the other population studies that used epithelial sampling methods. This also applies 
to a Brazilian study conducted cross-seasonally over two years. The aim of this study was to 
identify any seasonality in virus detection in CRS patients. The authors hypothesised that 
there may be a continual viral presence either in excess/of a different nature/both in CRS 
patients at times when virus circulation is generally low in healthy populations. A discovery 
such as this might add weight to the theory that a continual viral presence contributes to 
chronic inflammatory symptoms in CRS. The investigators took samples of nasal and 
maxillary mucosa as well as nasal lavages from a reported 100 CRS patients at time of 
surgery. Patients were recruited both with and without polyps, none reported any current 
respiratory illness, but on closer inspection the cohort appears to be only 93 patients. They 
found a 54% overall viral detection rate. This was comprised largely of MPV and RV and 
was concentrated in winter/spring of 2010 and spring of 2011. The authors thus concluded 
that these viruses are unlikely to be contributing to CRS symptoms given these are times of 
high viral circulation in the general population, however they investigated no specific control 
subjects in their work. [173] Another group lacking a control group is that of Abshirini et al. 
who collected mucus specimens during FESS from 53 CRSwNP and 23 CRSsNP patients 
over the course of nearly a year in Iran. No specific cellular collection was undertaken and 
the mucus collection method was not detailed. The mucus specimens underwent RT-PCR 
specifically for RV and RSV (it is unclear why the authors chose only these pathogens) and 
found a 22% and 9% presence of these respectively, with a 6% dual presence. From these 
results the authors concluded these viruses have a role in CRS pathogenesis, but without a 
healthy control group and any intra-cellular collection method such a conclusion cannot be 
validated. [174] Some earlier work (1992 to 1994) done in West Virginia also investigated 
viral presence in CRS patients only, and did not use a control group for comparison. 
66 
 
However, this study was undertaken during the beginnings of commercial PCR availability 
and so was focused more on the detection method rather than the identification of viruses for 
its own merit. 20 patients undergoing sinus surgery (no season was identified) had tissue 
samples extracted. These were analysed for RSV and AdV presence using both PCR and 
more traditional methods, as well as simultaneous bacterial culture. Four patients (20%) were 
positive for RSV using PCR, and none were positive for AdV using PCR. One sample each 
was positive for the aforementioned viruses using immunofluorescence and viral culture. 
40% of the samples were positive on bacterial culture (anaerobes > H. influenzae > S. 
pneumoniae > P. aeruginosa), but this was not discussed in great depth. Of note would have 
been any association between bacterial and viral presence. However this is unlikely to have 
displayed any significance either way given the experimental conditions and sample size. 
[175]  
 
Despite some areas of concern, common to all of these studies are the viruses most prevalent 
in various populations. Exact numbers vary, but these include RV, influenza, PIV, RSV, 




Table 1.2 Summary of published virome studies
Study Sample size Viruses screened Season Collection method Results and author’s conclusion 
Abshirini et al, 
2015 [174] 
0 controls, 23 CRSsNP, 53 CRSwNP RSV, RV All (one year) Sinonasal mucus High prevalence of RV and RSV; 28.94% 
RV-positive, 11.84% RSV-positive, 7.89% 
both 
Cho et al, 2013 [45] 50 controls (thyroid/tonsil surgery), 49 
CRSsNP, 62 CRSwNP 
AdV, BoV, CoV, EnV, 







Viruses and CRS may be associated; 50.5% 
CRS lavage positive vs. 26% control, 64% 
CRS scrapings positive vs. 15% control. RV 
most prevalent 
Jang et al, 2006 
[44] 
27 controls (OSA surgery), 39 CRSsNP, 
0 CRSwNP 
RV Late winter, spring Nasal lavage, IT 
scrapings 
RV may be associated with CRS; 21% CRS 
scrapings positive vs. 0% controls, all lavages 
negative 
Liao et al, 2014 
[170] 
53 controls (septoplasties), 61 CRSsNP, 67 
CRSwNP 
CoV, influenza, PIV, RSV All (two years) MM scrapings CRS and virus likely not linked, no correlation 
with disease severity; 75.47% controls 
positive vs. 73.77% CRSsNP vs. 68.66% 
CRSwNP 
Lima et al, 2015 
[173] 
0 controls, 32 CRSsNP, 60 CRSwNP AdV, BoV, CoV, EnV, 
influenza, MPV, RSV, RV 




Viruses in CRS seasonal; 54% positive, MPV 
most prevalent, peaks in winter and spring 
Ramadan et al, 
1997 [175] 
No controls, 20 CRS (polyp status 
unspecified) 
AdV, RSV All (two years) Mucosal biopsies 
(ethmoid/maxillary 
sinus) 
PCR more sensitive for viral detection than 
culture; 20% samples positive on PCR vs. 5% 
on culture 
Rowan et al, 2015 
[171] 
14 controls (skull base tumours), 8 
CRSsNP, 13 CRSwNP 
AdV, CoV, influenza, PIV, 
MPV, RSV 
Late winter, spring, 
summer, early 
autumn 
Viral swabs (MM/ 
anterior ethmoid) 
Viruses and CRS may be associated; controls 
all negative, CRSsNP 80% positive, CRSwNP 
20% positive. Virus associated with severity 
in CRSsNP 
Wood et al, 2011 
[172] 
2 controls (skull base tumours), 8 
CRSsNP, 5 CRSwNP 
AdV, BoV, CoV, influenza, 




(location not specified) 
Viruses and CRS unlikely related; no viral 




1.7.2 The Herpesviridae and CRS 
 
Viruses known to cause long-term latent infection often without significant upper respiratory 
symptoms include EBV, HHV6, HSV, VZV, HPV and CMV. These pathogens have a wide 
tissue distribution, and so lend themselves to investigation as potential initiating or 
perpetuating factors in CRS. Since the advent of large-scale PCR testing little research has 
been done into the prevalence of these in the sinonasal tracts. What has been done has 
focused largely on EBV and HHV6 and their potential role in nasal polyposis. A group in 
Hong Kong investigated the role of EBV in the pathogenesis of a wide range of tumours. 
They took healthy nasopharyngeal tissue samples during autopsy from patients without 
apparent EBV-related disease (ie. with presumably healthy nasopharyngeal mucosa). They 
found 80% (8/10 total) of these were positive for EBV. [176] The same group also 
investigated EBV presence in PCR-tested nasal polyp tissue.  They found the virus to be 
present in 69% (9/13) of their samples. [177] Researchers in Greece took this further in 2009, 
comparing nasal polyp and adjacent turbinate mucosa samples from 23 CRSwNP patients to 
turbinate samples from 13 patients undergoing nasal corrective surgery. The specimens 
underwent PCR testing for HPV, CMV, HSV, VZV, HHV6 and EBV. EBV was detected in 
35% of the polyp samples (8/23), HPV in 13% (5/23), HSV in 8% (2/23) and CMV in 4% 
(1/23). Only the adjacent turbinates of patients positive for HPV in their polyps were positive 
for viruses (HPV in 2/46, 4%). All other disease and control samples were negative for the 
viruses tested. Based on their findings the authors concluded that EBV presence influences 
the pathogenesis of nasal polyps, and that HPV, HSV and CMV are likely to play less 
important roles. This would be more compelling if the control population were composed of 
CRSsNP patients, if the CRS and control groups were composed of similar numbers, and if 
the one sample positive for CMV had shown statistical significance. [179] Additional work 
69 
 
was undertaken in Italy in 2014 again comparing nasal polyp and adjacent turbinate mucosa 
samples from 35 CRSwNP patients taken at time of FESS. Pre- and post-operative IT or MT 
(middle turbinate) scrapings were also taken in 29 of the 35 patients. HHV6 was found in 
12.1% of samples (3/35 polyps, 11/31 adjacent turbinates, 1/29 preoperative scraping). EBV 
was found in 10.5% (8/35 polyps, 3/31 turbinates, 1/29 preoperative and 1/29 postoperative 
scraping). CMV was found in 1.6% (1/35 polyps and 1/29 postoperative scraping) and HSV 
in 1.6% also (2/35 polyps). These samples were also investigated for more common URT 
viruses (influenza, RSV, AdV, MPV, CoV, PIV, RV, EnV and BoV). Only one preoperative 
scraping was positive (PIV). The authors drew similar conclusions to the aforementioned 
study; that EBV may have an initiating or perpetuating role in polyp development in CRS, 
and that the other viruses likely do not. [180] There was, however, no appropriate control 
group in this study with polyp samples only compared to adjacent tissue from the same 
patients. This tissue adjacent to polyps in CRSwNP patients is undoubtedly still affected by 
the disease. Although not explicitly stated in either study, sampling of all mucosal layers 
rather than pure epithelial sampling was likely chosen here as EBV has previously been 
found in deeper lymphoid tissue. [177, 178] A summary of the investigation into the 
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1.8 The bacterial microbiome of chronic rhinosinusitis 
 
The bacterial microbiome of the sinonasal passages in health and disease has received 
significant attention in the recent past. Work is underway to characterise it and devise 
methods of manipulating it for therapeutic ends. In-depth discussion of the CRS microbiome 
is beyond the scope of this thesis, however some findings are generally agreed upon. There 
appears to be a dysbiosis within CRS with a similar bacterial burden to that seen in healthy 
individuals, but CRS sinuses lack biodiversity. [186] Typically this lack of biodiversity 
manifests as increased prevalence of species seen as more traditionally pathogenic, with a 
reduction in prevalence of bacteria more traditionally seen as commensal. [187] Various 
studies have been undertaken on varying scales using varying collection methods, laboratory-
based analysis and bioinformatic techniques. As such the resulting data have been difficult to 
compare. An excellent meta-analysis by Wagner Mackenzie et al. attempted to standardise 
and re-analyse many of the existing studies. They concluded the bacteria most prevalent both 
in the healthy microbiome and in that of CRS are Staphylococcus, Propionibacterium, 
Corynebacterium and Streptococcus species, as well as an unclassified lineage of 
Actinobacteria. The CRS microbiome was confirmed as dysbiotic, with reduced relative 
abundance of Actinobacteria and Propionibacterium species and an increased abundance of 
Corynebacterium species. When the dataset from normal individuals was analysed without 
Burkholderia or Propionibacterium species network fragmentation was increased. This 
suggests these may be “gatekeeper” genera with roles in maintaining the healthy microbiome. 
[188] 
 
Little investigation has been undertaken into the changes induced in the respiratory 
microbiome in the presence of viral infection. What has been studied has focused largely 
either on the lower airways or on animal models; it is important to note that replication of the 
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human microbiome in an animal model is exceedingly complex. Wang et al. showed that 
pathogen-free mice (lacking S. aureus colonisation as well as other relevant inflammatory 
cytokines) were more susceptible to influenza-mediated death. [189] Leung et al. recruited 
bacterial pneumonia patients both with and without H1N1 influenza infection and compared 
their oropharyngeal microbiota. They found a significant increase in Pseudomonas, Bacillus 
and Ralstonia species in the influenza group. This was accompanied by significant reductions 
in Prevotella, Veillonella and Neisseria species (all normal oral commensals). The authors 
did not investigate the microbiome of the lower airways in these patients, despite their 
disease being focused there. [190] de Steenhuijsen et al. focused on children with RSV 
infection of the lower airway and found clusters of patients with significantly more H. 
influenzae, Streptococcus, Corynebacterium, Moraxella or S. aureus. The presence of any of 
these also correlated with more severe disease. Again, the microbiome samples were taken 
from the nasopharynx despite the virus under investigation existing in the lower airways. 
[191] One study did focus purely on the upper airways; nasopharyngeal swabs were taken 
from 177 patients with clinically suspected viral URTI. 47 of these were virus negative on 
PCR with the remainder positive for one of either influenza, RV, MPV or RSV. These swabs 
were compared with 48 swabs from healthy controls. This showed significant reduction in 
bacterial diversity and loss of bacteria known to form part of the core healthy bacterial 
microbiome. The authors also found significant increase in particular URT bacteria known to 
colonise the healthy airway, but also often implicated in respiratory disease (including S. 
aureus, H. influenzae, S. pneumoniae and M. catarrhalis). No difference was found in 
microbiota profiling between the different virus groups, however with only 23 to 28 patients 
in each statistical significance was unlikely given the enormous diversity seen in these 
profiles between individuals. During recruitment of controls one patient identified was 
asymptomatic but positive for influenza A. This individual displayed a bacterial microbial 
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profile similar to those of non-virus-infected controls. Overall these observations suggest 
viral susceptibility and the manifestation of viral disease may be influenced by virally-
























1.9 Cellular infiltrates and chronic rhinosinusitis 
 
As previously mentioned CRS has traditionally been classified into two phenotypes; CRSsNP 
and CRSwNP. A significant degree of heterogeneity exists amongst patients within each of 
these phenotypic classifications however, and so their validity has been debated in recent 
years. Clear definition of CRS endotypes is valuable as it may predict disease progression, 
disease recurrence and response to treatment, and may identify therapeutic targets. Studies 
have investigated and attempted to cluster CRS endotypes based on downstream molecular 
and cellular markers, and eosinophilia and different T cell populations have been identified as 
important clusters. [193-195] 
 
1.9.1 Eosinophilia and CRS 
 
Eosinophils normally make up about 1-3% or peripheral white cells and play important roles 
in fighting viral and parasitic infections. They have been implicated in T cell antigen 
presentation, and mediate allergic responses. Their degranulation has been postulated to be 
partially responsible for the inflammation and tissue damage seen in CRS. Tissue 
eosinophilia has been classically associated with CRSwNP and elevated levels of Th-2 
cytokines, whereas CRSsNP is associated with tissue neutrophilia and elevated Th-1 
cytokines. [195] Again there are many individuals whose disease does not follow these 
inflammatory and phenotypic patterns, but when present excessive eosinophilia is associated 
with more extensive disease, worse symptom scores and higher recurrence rates. [196-198] 
Several chemokines and cytokines have been implicated in augmenting eosinophil survival 
and facilitating their differentiation in CRS mucosa, [199, 200] but the factors inducing their 
presence in the first instance remain uncertain. Given the known association of eosinophils 
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and viral infection, it is not unreasonable to hypothesise that viruses may be an eosinophilia-
inciting factor in CRS.  
 
1.9.2 T lymphocytes and CRS 
 
T lymphocytes are another cellular population of significant interest in CRS that form 
important parts of the immune response to respiratory viral infection. [201, 202] CD4+ T cells 
and their associated cytokines have long been implicated in CRS pathogenesis. [203] 
Cytotoxic CD8+ T cells have been investigated in less depth in CRS, but do appear to have 
roles in modulation of autoimmune and allergic pathologies outside of their more classical 
cytotoxic activity. [204] CD8+ T cells have been found in greater numbers in CRS mucosa 
and have been associated with their own set of pro-inflammatory cytokines which may be 
contributing to disease pathogenesis. [204-206] As is the case for other T cell types CD8+ T 
cells have regulatory subtypes (tissue-resident memory T cells, Trm); these express CD103. 
CD103+ T cells (also known to be expressed on CD4+ regulatory T cells) have roles in 
controlling the potentially damaging effect of cytotoxic T cells when present in high 
numbers. [207] As yet the CD8+ and CD103+ subsets of Trms have not been investigated in 










Summary of the systematic review of the literature 
 
CRS is an extremely prevalent and costly disease of the nasal and paranasal sinus mucosa 
that is difficult to treat. Symptoms include nasal obstruction, anterior rhinorrhoea, PND, 
headaches or facial pain/pressure and anosmia as well as other non-specific systemic 
complaints. Disease severity and response to treatment can be evaluated using various tools, 
including validated patient reported outcome measures such as the SNOT-22 or ADSS, and 
the objective LMS, LKS or MLK.  
 
There are a number of theories as to the aetiopathogenesis of CRS. These include the 
bacterial, immune and fungal hypotheses. The bacterial hypothesis encompasses microbiota 
dysbiosis, S. aureus overgrowth, SAg production and biofilm formation. The immune 
hypothesis includes disruption of the epithelial mechanical barrier, innate and adaptive 
immune systems. The fungal hypothesis was initially seen as a very promising element that 
might unite all cases of idiopathic CRS. It has lost momentum due to lack of consensus in 
results and the inability of large-scale antifungal trials to demonstrate significant clinical 
benefit. A more recent school of thought highlights viruses as possible contributors as well. 
Anecdotally it is extremely common to encounter CRS patients who report having contracted 
the common cold with the development of CRS thereafter. Viruses are associated with other 
chronic inflammatory diseases (such as asthma, COPD and CF) and bacterial infections of the 
respiratory tract. They are also associated with eosinophilia and T cell infiltrates, which are in 
turn associated with more severe CRS that is more difficult to treat and more likely to 
relapse. The combination of these two observations has ignited interest in the role that viruses 
may play in the development of CRS. Also driving this interest are known mechanisms of 
viral-bacterial co-infection in the respiratory tracts. These include effects on epithelial barrier 
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function, bacterial binding, innate and adaptive immunity, the respiratory microenvironment, 
direct viral-bacterial interactions and a defective IFN response. These may be pertinent to 
CRS given the role of bacteria in its aetiopathogenesis; the bacterial microbiome is under 
intense scrutiny in the current literature. It is generally accepted that CRS sufferers exhibit a 
dysbiosis with reduced biodiversity, reduced commensal bacteria and increased pathogenic 
bacteria in their sinuses. However, minimal investigation has been undertaken with regards 
the effect of viruses on the respiratory microbiota. 
 
Common URT viruses include RV, influenza, CoV, AdV, PIV, RSV, MPV and less 
commonly BoV and EnV. The Herpesviridae (EBV, HHV6, HPV, CMV, VZV and HSV) are 
also overwhelmingly prevalent, but their near-ubiquity and capability of remaining latent has 
made interpretation of their presence difficult. Methods for collection of these viruses in the 
sinonasal passages have not yet been investigated in any depth. Population virome studies 
have formed the bulk of the literature on the possible role of viruses in CRS. However, 
differences in patient cohorts, collection methods, season of collection and the viruses for 
which investigators assayed make comparison of these data difficult. Overall it would seem 
the two disease entities are correlated, but more comprehensive, standardised investigation 











1. To establish and validate a standardised method for viral sampling in the sinonasal 
passages 
2. To characterise the sinonasal virome in CRS and to investigate correlation of viral 
presence with disease severity 
3. To investigate association of eosinophilia and T lymphocytes with viral presence in 
CRS 
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Background: With the emergence of the microbiome as an important factor in health and 
disease in the respiratory tract standardised, validated techniques are required for its accurate 
characterisation. No standardised technique has been reported specifically for viral sampling 
in the sinonasal passages.  
Aim: To optimise viral sampling techniques from the sinonasal cavity.  
Methods: Sterile cytology brushes were used under endoscopic guidance to sample the 
sinonasal mucosa at time of endoscopic sinus surgery at both the MM and IM. DNA and 
RNA were extracted from the samples and underwent PCR or RT-PCR testing respectively 
for a panel of fifteen common URT viruses.  
Results: 24 adult patients were recruited for this study. 18/24 (75%) patients were positive for 
virus in at least one site, while 8/24 (33%) were positive for virus at both sites. The mean 
number of viruses identified at the two sites were similar (0.875 +/- 0.899 at the MM versus 
0.750 +/- 1.032 at the IM). 6/24 (25%) of patients showed no virus at either site, while 3/24 
(12.5%) demonstrated the same viral species at both sites.  
Conclusion: Although the number of viruses present at different sites with the nasal cavity are 
similar, discord exists in the viral species between sites. It is therefore recommended that 
both sites are sampled in the clinical and research setting better to characterise the viral 











The role of the healthy human microbiome in prevention and eradication of disease is an area 
of burgeoning interest in recent years. The interplay between various colonising organisms, 
their relative abundance and the importance of a fine microbial balance has been shown to be 
essential for normal functioning of multiple organ systems, not least respiratory. [208, 209] 
Conversely, disruption of this balance between viruses, bacteria and single-celled eukaryotes 
has been implicated in numerous disease processes, including acute infective processes as 
well as many chronic inflammatory diseases. [208] 
 
Microbial dysbiosis (specifically bacterial) has been implicated in several respiratory 
diseases, including asthma [210] and CRS. [211] Persistent nasal and paranasal sinus 
inflammation characteristic of CRS affects up to 16% of the western population [212] and 
manifests as nasal congestion, facial pain or pressure, anterior or post-nasal drainage, and 
reduction or loss of smell. [2] Although the exact aetiopathogenesis of this condition remains 
elusive, it is considered multifactorial in origin. Current theories include the fungal 
hypothesis, the bacterial hypothesis (implicating dysbiosis with S. aureus overgrowth, SAg 
production and biofilm formation) and an overactive immune response (resulting in chronic 
inflammation and defective mechanical and innate immune barriers to infection in the CRS 
population). [23] An area that is anecdotally suggested to play a role in CRS pathogenesis is a 
viral dysbiosis. [44, 45] This is due to self-reports by many CRS patients that their symptoms 
almost invariably developed after an initial viral URTI. Research into the ideal method to 
sample the sinonasal bacterial microbiome is ongoing, [213] however similar efforts to 




Studies attempting to investigate the upper respiratory virome are limited. The lack of 
standardisation in sampling has led to conflicting results regarding the presence of virus and 
the composition of the virome. Collection techniques employed thus far include nasal washes, 
aspirates, brushings and traditional viral swabs, with viral analysis performed by PCR. [44, 
45, 170-180] Few studies have compared sampling methods; Heikkinen et al. found no 
difference in the detection of childhood influenza comparing nasal swabs and aspirates. [181] 
Spyridaki et al. found a higher detection of RV in nasal lavages compared with nasal 
brushings but found no difference in any other viruses tested when comparing these to nasal 
aspirates and swabs. [182] To date there have been no studies that have compared different 
sites within the sinuses and nasopharynx in terms of viral detection. 
 
The aim of the study here presented was to establish differences in viral detection and species 
sampled from different sinonasal sites, in an effort to validate and standardise viral collection 














2.3 Materials and methods 
 
 
2.3.1 Study participants 
 
Patients for this study were recruited from the tertiary rhinologic practices of the two senior 
authors (PJW and AJP). This study was carried out in accordance with the recommendations 
of the Central Adelaide Local Health Network Ethics Committee (HREC/15/TQEH/132). 
The protocol was approved by the same. All subjects gave written informed consent in 
accordance with the Declaration of Helsinki. Patients were included in this study if they were 
older than eighteen years of age and were undergoing endoscopic surgery. Control patients 
consisted of patients with an absence of clinical or radiologic evidence of CRS. CRS patients 
fulfilled the diagnostic criteria for CRS as outlined in the American guidelines. [214] The 
radiological severity of disease was scored for all patients using the LMS. [77] 
 
2.3.2 Sampling and processing 
 
Using an aseptic technique, endoscan cytology brushes (McFarlane Medical, Melbourne, 
Australia) were used to sample the sinonasal mucosa (figure 2.1) of the left and right MM 
and IM of each patient. This was done under endoscopic visualisation with caution to avoid 
cross-contamination from neighbouring tissue. The samples were then placed in a viral 
transport medium (89% Roswell Park Memorial Institute medium supplemented with 9% 
foetal bovine serum, 1% amphotericin B and 1% penicillin streptomycin (all Gibco by 
ThermoFisher, Waltham, USA)) and immediately transported on ice to the laboratory for 
processing. Sample material was removed from the brushes and centrifuged at 4°C and 
1700rpm for seven minutes in order to isolate cellular material. The supernatant was 
discarded, after which samples were stabilised with 35µL RPE Buffer (Qiagen, Hilden, 
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Germany) and 3.5µL beta-mercaptoethanol (Gibco by ThermoFisher, Waltham, USA) and 
stored at -80°C.  
Samples were thawed in batches to undergo RNA and DNA extraction using an AllPrep 
DNA/RNA Mini Kit (Qiagen, Hilden, Germany). This yielded DNA samples of 200µL 
(average concentration 96.37ng/µL, range 10.3 to 383.3ng/µL) and RNA samples of 60µL 
(average concentration 58.58ng/µL, range 4 to 247.3ng/µL). 
  
 




Extracted DNA and RNA were stored at -80°C until batch testing for a range of URT viruses 
using real-time PCR. The panel included RV, influenza A-C, PIV 1-4, RSV A and B, CoV 
HKU-1, OC43, NL63 and 229E, EnV, MPV, AdV, BoV, polyomaviruses WUPyV and 
KIPyV, EBV, CMV, HHV6, HSV 1 and 2, and VZV. All DNA extracts first underwent an 
ERV3 assay (present as two copies per human diploid cell) in order to confirm respiratory 




Briefly, DNA extracts were screened for ERV3, AdV, BoV, WUPyV, KIPyV, CMV, EBV, 
VZV, HSV 1 and 2 and HHV6 using an identical set of conditions previously optimised so as 
not to compromise sensitivity (table 2.1). Said conditions were 8 pmole of each primer, 
3.2pmol of the respective probe(s) and 2µL of template, made up to a final reaction volume 
of 20 µL using the Bioline Sensi Mix II Probe PCR mix kit (Bioline Australia). Details of the 
target genes, primer and probe sequences are summarised in tables 4 and 5. Samples then 
underwent the following cycling conditions: 94°C for two minutes, followed by 45 cycles of 
95°C for fifteen seconds and 60°C for sixty seconds. The RNA extracts were tested for RV, 
influenza A to C, PIV 1 to 4, RSV A and B, CoVs HKU-1, NL63, OC43 and 229E, EnV and 
MPV (table 2.2) using identical quantities of primer, probe and template to the DNA 
reactions but with the Bioline SensiFAST Probe One-Step RT-PCR kit (Bioline, Sydney, 
Australia). There were two exceptions to these quantities; the IV A/B duplex where 
asymmetric probe amounts were used (6.4pmol and 3.2pmol respectively) and the RV assay 
where 16pmol of probe was used. Samples then underwent the following cycling conditions: 
45°C for twenty minutes, and 45 cycles of 95°C for fifteen seconds and 60°C for sixty 
seconds. All samples were run with both positive and negative controls; the positive controls 
were either previously established clinically positive samples, or synthetic controls specific 
for each assay. All cycling was conducted on Viia7 instruments (ThermoFisher, Scoresby, 









Primer, probe sequences (5'-3') Source 
















STAg  CACAGGTGGTTTTCTATAAATTTTGTACTT  GAAGCAGTGGGATGTATGCATTC 
YAK-TGCATTGGCATTCGTGATTGTAGCCA-BBQ 





MIE AACTCAGCCTTCCCTAAGACCA  GGGAGCACTGAGGCAAGTTC 
FAM-CAATGGCTGCAGTCAGGCCATGG-BHQ1 
[218] 
15 Epstein Barr 
virus 















gD CGCCAAATACGCCTTAGCA  GAAGGTTCTTCCCGCGAAAT 
VIC-CTCGCTTAAGATGGCCGATCCCAATC-BHQ1 
[218] 










Reaction mix Virus Target gene Primer, probe sequences (5'-3') Source 






Influenza A Matrix  CTTCTAACCGAGGTCGAAACGTA GGTGACAGGATTGGTCTTGTCTTTA 
Q670-TCAGGCCCCCTCAAAGCCGAG-BHQ2 
[224] 
3 Influenza B Matrix  GCATCTTTTGTTTTTTATCCATTCC  CACAATTGCCTACCTGCTTTCA 
FAM-TGCTAGTTCTGCTTTGCCTTCTCCATCTTCT-BHQ1 
[225] 





4 RSV A Nucleocapsid AGATCAACTTCTGTCATCCAGCAA   TTCTGCACATCATAATTAGGAGTATCAAT 
FAM-CACCATCCAACGGAGCACAGGAGAT –BHQ1 
[226] 






























































CATATAAGCATGCTATATTAAAAGAGTCTC  CCTATTTCTGCAGCATATTTGTAATCAG 
FAM-TGYAATGATGAGGGTGTCACTGCGGTTG-BHQ1 
[231] 






2.3.4 Statistical analysis 
 
Statistics were performed using software from Scientific Python, namely SciPy and pandas 
through the Jupyter Notebook interface. [233] McNemar’s test was used to test for 
significantly different proportions of viral positivity between sites. Paired Student’s t test was 
used to compare the mean number of viruses detected between sites. Percentage agreement 
was calculated for viral detection between both sites for both number and species of viruses 
detected. Chi square test was used to investigate any correlation between viral presence and 





















2.4.1 Patient characteristics 
 
24 patients were recruited at time of endoscopic surgery; this included fourteen men and ten 
women, with an age range of 19 to 79 years, and a mean age of 51 years. Seven patients had 
CRSsNP, eight had CRSwNP and nine were controls. Demographics and patient 
characteristics are summarised in table 2.3. All patients in the CRS groups underwent FESS, 
while those in the control group underwent trans-sphenoidal resections of pituitary masses. 
 
Mean age (years) 46.5 45.6 61.1 
Sex 3 M, 6 F 4 M, 3 F 7 M, 1 F 
Diagnosis 9 controls 7 CRSsNP 8 CRSwNP 
 
Table 2.3 Summary of patient demographics and characteristics. 
 
2.4.2 Viral detection and analysis 
 
ERV3 was detected in all patient samples, with a median Ct of 22.5 (range 19.3-28.0), 
showing adequate cellular material was captured throughout the collection and DNA 
extraction phases. 18 patients were positive for at least one virus in at least one site (18/24, 
75%), while six (6/24, 25%) were negative for any of the viruses for which the samples were 
screened (table 2.4). Similar rates of viral detection were seen between the MM and IM 
overall (52% positivity at the MM versus 48% at the IM; p= 0.55, McNemar’s test). The 
mean number of viruses detected at the MM was 0.875 +/- 0.899, versus 0.750 +/- 1.032 at 
the IM. The mean number of viruses detected did not differ significantly between both sites 
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(p=0.57, paired t test). Interestingly the majority of patients (63%) did not show an intranasal 
correlation between sites. Of the nine patients demonstrating similar findings at both sites, 
only three demonstrated viral presence with six showing an absence of virus at all sites. 
Fifteen patients were inconsistent between the two sites; this included 4 patients who 
exhibited virus or viruses at both sites but of different species at each (table 2.4) These 
findings correspond to a percentage agreement of only 31 between the MM and IM in terms 
of number of viruses detected (i.e. not accounting for viral species). When analysing for viral 
species there was only a percentage agreement of 27 between the sites. No correlation was 




Table 2.4 Viral species identified at middle and inferior meatuses.
Patient 
number 
Diagnosis Site of 
sampling 
Viruses identified Patient 
number 




1 Control MM None 13 Control MM EBV, HHV6 
IM None   IM EBV 
2 CRSwNP MM None 14 CRSsNP MM None 
IM None   IM Influenza A, 
HHV6 
3 CRSsNP MM None 15 CRSsNP MM None 
IM None   IM EBV 
4 Control MM None 16 CRSwNP MM EBV 
IM None   IM None 
5 CRSwNP MM None 17 CRSsNP MM HHV6 
IM None   IM None 
6 Control MM None 18 Control MM HHV6 
IM None   IM None 
7 CRSwNP MM Influenza A, HHV6 19 CRSwNP MM None 
IM Influenza A, HHV6   IM EBV 
8 Control MM HHV6 20 CRSwNP MM EBV, HHV6 
IM HHV6   IM None 
9 Control MM EBV, HHV6 21 CRSsNP MM HHV6 
IM EBV, HHV6   IM None 
10 CRSsNP MM HHV6 22 CRSwNP MM EBV, HHV6 
IM EBV   IM None 
11 CRSsNP MM Influenza A 23 CRSwNP MM PIV2 
IM Influenza A, EBV   IM None 
12 Control MM HHV6 24 Control MM None 






A standardised, validated technique for viral sampling in the sinonasal passages has not yet 
been described. This study shows a significant discrepancy in viral presence and species 
between just two of the sites commonly sampled, highlighting the need for such a 
standardisation. This indicates that viral sampling needs to be conducted with a cytobrush in 
both the IM and the MM. 
 
Collection variability has the potential to impact respiratory viral detection significantly. The 
sample volume and location, as well as the documented uneven distribution of viruses within 
the nasal cavity, can all contribute to false negatives. [234] Given that clinically relevant, 
actively replicating viruses of the URT are intra-cellular and largely reside in the upper 
epithelial layers of the mucosa, [118] adequate cell sampling is an important consideration 
when searching for viruses. Traditional viral sampling brushes have the advantages of 
causing less trauma to the delicate mucosa and thus less discomfort to a conscious patient, but 
risk sampling largely secreted elements rather than the cells themselves. [182] Viruses do 
certainly reside in these secretions, but this may not necessarily represent actively replicating 
virus causing disease. For these reasons we elected to use cytology brushes for this study. 
Cytology brushes are designed specifically for cell sampling due to their larger and more 
rigid design than traditional viral sampling brushes. Although this may potentially increase 
the risk of trauma or discomfort to the awake patient, when used in the anaesthetised patient, 
as was the case in this study, they have the significant advantage of increased cellular 




As mentioned viral yields are also difficult to compare in respiratory samples, as sample 
volume can vary widely. The samples here averaged a DNA concentration of 96.37ng/µL and 
an RNA concentration of 58.58ng/µL, but with ranges of 10.3 to 383.3ng/µL and 4 to 
247.3ng/µL respectively. To minimise the impact of this variability on results all samples 
underwent an ERV3 assay prior to PCR. This has been identified previously as a positive 
indicator of respiratory sample quality, and all samples were well within previously published 
target ranges. [235, 236]  
 
Viral sampling is traditionally performed from the inferior nasal septum and anterior nasal 
floor as they are easily accessible and cause minimal patient discomfort. The posterior 
nasopharyngeal wall is also traditionally endorsed, but confirmation of access to this site is 
difficult without endoscopic equipment. There is no evidence however that these three sites 
are any more or less appropriate. These areas may indeed be less than ideal due to their 
relative proximity to airborne pathogens (and therefore risk of contamination), their distance 
from areas of particular interest (such as the paranasal sinuses), and the tendency for pooling 
of potentially contaminating secretions in these areas. The MM (sampled in our study) 
remains relatively simple to access but is further away from potential sources of 
contamination, and receives drainage from a much wider area including the maxillary, frontal 
and anterior ethmoid sinuses. There are indeed a number of other sites in the nasopharynx not 
investigated here, for example the superior meatus, the sphenoethmoidal recess and the post-
nasal space, however these are difficult to reach without endoscopic equipment that is not 
readily available in the primary care setting, and can be subject to contamination from other 
more anterior sites during insertion and removal of sampling instruments. Should these areas 
demonstrate greater viral presence than the MM and IM the specialist input required to access 
the sinuses themselves would likely delay or miss altogether the diagnosis and window for 
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anti-viral treatment. Large-scale economic viability of the collection method here proposed 
also warrants mention; pooling of viral samples from the same patient prior to analysis and 
limitation of viral testing to a smaller panel of more prevalent, clinically relevant pathogens 
would be prudent, however selection of such a panel requires further investigation.  
 
Common, clinically relevant upper respiratory viruses are largely of the RNA subtype, and 
include RV, influenza, RSV and MPV, and to a lesser extent CoV, PIV, and EnV. Of the 
DNA viruses here investigated AdV is certainly a notable URT pathogen. BoV has been 
linked largely with lower respiratory illness. [237] The other DNA viruses here investigated 
were chosen not primarily for their clinical relevance in viral respiratory disease, but instead 
for either their near-ubiquity, their ability to remain latent in the respiratory tract, or both. 
EBV and HHV6 have here shown themselves to be particularly useful in testing viral 
sampling methods as they are almost omnipresent in the adult sinonasal passages, and are 
rarely entirely cleared after first infection. 
 
Effort was made in this study to identify any correlation between control/CRSsNP/CRSwNP 
status and viral presence. Patient reports of recent viral infection, SNOT-22 scores, LMS, 
LMK and RT-PCR Ct values were collected for all patient and samples, but the sample size 
here was too small to demonstrate any significant differences. The inclusion of the extremely 
common herpesviruses (seen, as expected, in many of our controls) also skewed any such 
results. This is an area that requires significant further investigation. 
 
Neither of the sites from whence samples were taken were more or less likely to be positive 
than the other. Our observation that the MM and IM only completely agree in terms of viral 
presence or absence as well as viral species in 27% of cases indicates a significant proportion 
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of viruses present would not be identified were only one site to be sampled. Our findings 
suggest viral sampling from the sinonasal passages should be taken from both sites in both 
nasal cavities. The sampling method here described has significant implications for further 
research into a field of emerging importance in both rhinologic and also respiratory disease 
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Background: Patients with CRS often implicate a viral URT infection as a disease-inciting 
event. However, the presence and identity of these viruses and their relationship to disease 
phenotype and severity in CRS patients is unknown. The aim of this study was to investigate 
the CRS virome in relation to disease characteristics. 
Methods: Endoscopically-guided sterile cytology brushes were used to sample the mucosa 
immediately prior to sinus surgery. DNA/RNA extracts underwent PCR/RT-PCR testing for a 
panel of common respiratory viruses. Disease severity data was collected from each patient 
prior to sampling: SNOT-22, ADSS, LMS and LKS.  
Results: 288 patients were included in the study; 71 controls, 133 CRSsNP) and 84 CRSwNP 
patients. Virus was significantly more prevalent in CRSsNP patients compared to controls; 
20.30% of CRSsNP versus 15.48% of CRSwNP and 7.04% of controls. LMS and LKS were 
worse in the CRSsNP group with virus than the CRSsNP group without virus (LMS 9.56 ± 
1.07 vs. 6.5 ± 0.43, LKS 6.07 ± 0.71 vs. 4.21 ± 0.32). SNOT-22 scores and ADSS were not 
significantly different for patients with virus versus patients without. 
Conclusions: Virus is more prevalent in CRSsNP patients and is associated with worse 
objective disease. This potentially implicates viruses in the pathophysiology of CRS, and as 











CRS is an inflammatory disorder of the nasal and paranasal sinuses occurring with and 
without nasal polyps (CRSsNP and CRSwNP). Although not objectively demonstrated, an 
initial viral insult is commonly described by patients prior to development of CRS. If viruses 
were demonstrated to play a role in CRS, novel prophylactic and/or therapeutic targets might 
be uncovered. 
 
Findings in previous studies investigating CRS and viruses are variable. [44, 45, 171, 172] 
Possible reasons include small sample sizes, unvalidated collection methods, seasonal 
limitation, heterogenous CRS cohorts and limited viral species screening. No studies to date 
have investigated disease severity in relation to viral presence. 
 
We aimed to investigate the sinonasal virome of CRS patients in relation to disease 
phenotype, to compare it to healthy controls, and to explore any association between more 
severe disease and viral presence. Cytobrush samples were taken from the sinonasal passages 
and DNA/RNA extracts underwent PCR for a number of viral species and strains. The 











3.3.1 Study participants and data collection 
 
Patient recruitment was undertaken from the tertiary rhinologic practices of two of the senior 
authors (AJP and PJW). The protocol was approved and the study was undertaken as per the 
Central Adelaide Local Health Network Ethics Committee (HREC/15/TQEH/132). 
Specifically, all participants gave verbal and written informed consent in accordance with the 
Declaration of Helsinki. Patients over the age of 18 years undergoing endoscopic surgery 
were included in this study. Control patients had no clinical, radiologic or endoscopic 
evidence of CRS. CRS patients met the American diagnostic criteria for such. [214]. All 
patients in the CRS groups were undergoing FESS, while those in the control group were 
undergoing trans-sphenoidal resections of pituitary masses or septoturbinoplasties. The 
symptomatic severity of disease was scored for all patients using the validated SNOT-22 and 
the ADSS. The radiological severity of disease was calculated using the LMS, and the 
endoscopic severity of disease was calculated using the LKS. 
 
3.3.2 Viral sampling and processing 
 
Viral sampling was undertaken using a previously published protocol from the authors’ 
department. [238] Briefly, endoscan cytology brushes (McFarlane Medical, Melbourne, 
Australia) were used to sample the left and right middle meatus (MM) and inferior meatus 
(IM) mucosa with an aseptic technique and under endoscopic visualisation. Samples were 
transported on ice and stored at -80°C in accordance with the aforementioned protocol. Prior 
to processing samples were thawed and underwent RNA and DNA extraction using an 
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AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany). DNA samples of 200µL were 
obtained (average concentration 96.37ng/µL, range 10.3 to 383.3ng/µL), as were RNA 
samples of 60µL (average concentration 58.58ng/µL, range 4 to 247.3ng/µL). 
 
3.3.3 Viral PCR/RT-PCR 
 
Specifics regarding PCR/RT-PCR methods appear in a previously published protocol. [238] 
In brief, DNA and RNA extracts were stored at -80°C until real-time PCR batch testing for a 
panel of respiratory viruses. These were AdV, BoV, CoV, EnV, influenza, MPV, PIV 1-4, 
RSV and RV. An initial ERV3 assay was undertaken in the DNA extract fractions prior to 
assays for the aforementioned viruses to ensure adequate sample quality. 
 
DNA extracts were tested for ERV3, AdV and BoV using the Bioline Sensi Mix II Probe 
PCR mix kit (Bioline, Sydney, Australia) under conditions previously described. [238] Said 
conditions had been optimised prior to testing so as not to compromise sensitivity. Details of 
the target genes, primer and probe sequences and cycling conditions have also been detailed 
previously. [238] RNA extracts were screened for CoVs HKU-1, NL63, OC43 and 229E, 
EnV, influenza A, B and C, MPV, PIV 1 to 4, RSV A and B and RV using the Bioline 
SensiFAST Probe One-Step RT-PCR kit (Bioline, Sydney, Australia). Again, target genes, 
primer and probe sequences and cycling conditions have been detailed previously. Cycling 
was conducted on Viia7 instruments (ThermoFisher, Scoresby, Australia). Viral detection 
was defined as a Ct of forty or less. 
 




Statistical analysis was performed using GraphPad Prism 7.03 (San Diego, USA). Chi-square 
test was used to compare viral detection in control, CRSsNP and CRSwNP patients, and to 
compare seasonal viral detection across those three groups. Kruskal-Wallis tests with post-
hoc pairwise comparisons were used to compare SNOT-22 scores, ADSS, LMS and LKS in 
control, CRSsNP and CRSwNP patients, and to investigate correlation of disease severity 
with viral species. Benjamini-Hochberg false discovery rate was used to correct p-values for 























3.4.1 Patient characteristics and viral detection 
 
288 patients were recruited: 71 controls, 133 CRSsNP and 84 CRSwNP (table 3.1). 45/288 
patients were virus-positive: 5 control, 27 CRSsNP and 13 CRSwNP (figure 3.1). The rate of 
viral positivity was significantly higher in the CRSsNP group (p<0.05). 
 
Diagnosis 71 controls 133 CRSsNP 84 CRSwNP 
Mean age (years) 53.82 48.79 51.05 
Number of female patients 35 70 29 
Season (spring:summer:autumn:winter) 15:13:16:27 28:33:51:21 19:15:30:19 
 
Table 3.1 Summary of patient demographics and characteristics for viral analysis. 
 
 
Figure 3.1 Detection of virus by PCR in controls and CRS patients. Number of patients 
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where virus was detected and not detected in controls, CRSsNP and CRSwNP. Comparison 
of positivity of virus detected, * p<0.05, Chi-square test. 
 
3.4.2 Correlation with disease severity 
 
Objective disease severity scores LMS and LKS revealed significantly worse disease in the 
CRSsNP virus positive cohort compared with the CRSsNP virus negative cohort (p<0.05, 
figure 3.2). No significant differences were observed in the control or CRSwNP cohorts. 
Subjective scores (SNOT-22 and ADSS) revealed no difference between patients with or 
without virus in any of the groups (figure 3.2). PCR Cts also revealed no difference between 
virus-positive or negative individuals (table 3.2).  












Adenovirus* 1* 67* 21* 4* 4* 33.57* 
Bocavirus 4 46.75 13.75 6.75 9.25 36.21 
Coronavirus 16 41.06 13.94 6.56 5.44 33.85 
Enterovirus 3 38 14 9.33 6.67 34.26 
Influenza 9 46 17 10.22 7 35.44 
Parainfluenza 3 31 16 14 10.33 32.25 
Rhinovirus 16 38.19 14.88 9.88 6.5 29.02 
RSV* 1* 47* 19* 7* 12* 38.09* 
 
Table 3.2 Details of virus-positive patients, including viral species, mean severity scores and 
cycle threshold values. *Indicates viral species for which only one patient was positive, so 





Figure 3.2 Objective (top) and subjective (bottom) disease scores in virus negative and 
virus positive patients. Grouped and compared by diagnosis (control, CRSsNP or 
CRSwNP), * p<0.05, Kruskal-Wallis tests. 
 
3.4.3 Viral species detection and seasonal spread 
 
Viral species detected did not vary significantly from previously published studies; these 
were largely RV and CoV (tables 3.2 and 3.3 and figure 3.3). Peak viral detection occurred in 
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spring and winter; there was no significant difference in detection when analysed by season 
(figure 3.4). 
 
Viral species +/- strain Number of positive 
control patients 
Number of positive 
CRSsNP patients  
Number of positive 
CRSwNP patients 
Adenovirus 1 0 0 
Bocavirus 1 2 1 
Coronavirus HKU 1 0 1 
Coronavirus NL63 2 3 1 
Coronavirus OC43 1 2 3 
Coronavirus 229E 0 1 1 
Enterovirus 1 1 1 
Influenza A 0 7 1 
Influenza B 0 1 0 
Influenza C 0 0 0 
Parainfluenza 1 0 0 0 
Parainfluenza 2 0 0 1 
Parainfluenza 3 0 1 1 
Parainfluenza 4 0 0 0 
Rhinovirus 1 13 2 
RSV A 0 0 1 
RSV B 0 0 0 
 





Figure 3.3 Viral species detected by PCR in virus positive patients. Control compared 
with CRS. 
 







This study identified common respiratory viruses as more prevalent in CRSsNP patients than 
in controls. It is the first study to demonstrate their significant association with more severe 
radiological and endoscopic disease in CRSsNP patients but not CRSwNP patients. 
 
The lack of any significant difference in subjective symptom scores in any of the groups is 
not unexpected. Absence of correlation between subjective and objective measures of disease 
severity has been well documented. [82] Although the inclusion of non-rhinologic questions 
in the SNOT-22 score is a possible explanation, no difference was observed when using the 
more specific ADSS. Another possible explanation may the timing of sampling. As most 
viruses tested in the assay are shed from the nasopharynx up to three weeks after symptom 
resolution it is possible that sampling occurred either during this time, or early in the 
infection prior to symptom development. 
 
The viruses identified largely consistent with those seen in previous CRS studies, with the 
exception that this study did not identify MPV. The main viruses observed across all cohorts 
were RV and CoV, with influenza featuring strongly in the CRS group. However, it seems 
likely there is no one virus with a particular contribution to CRS not also seen in the general 
population. The size of the virus-positive cohort limited sub-analysis of viral species/strains 
with regard to disease severity. As such we were unable to determine whether one particular 
viral species is associated with worse disease. 
 
Seasonality is an important concern when sampling for respiratory viruses. These are known 
to be most prevalent in winter and the early part of spring, an observation supported by this 
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study. Importantly we also showed strong viral positivity in summer and autumn. This 
highlights a clear short fall of previous CRS virome studies that limited sampling to winter 
and spring.  
 
The mechanisms underlying the viral contribution to CRS are unknown. Similarly unknown 
is whether the higher rates of viral infection here observed are a cause or a consequence of 
CRS. CRS has been well established as a bacterial disease, encompassing bacterial 
overgrowth, SAg and biofilm formation, and disruption of the microbiome. [16] The link 
between the bacterial and viral hypotheses of CRS aetiopathogenesis may lie in the ability of 
viruses to prime the airways for bacterial infection. Viruses damage the epithelial barrier by 
increasing mucus production, reducing ciliary presence and reducing tight junction 
expression. [118-120, 122, 159, 160] Viruses bind directly to bacteria and upregulate host 
cell surface molecules to facilitate bacterial-host adherence. [126, 131, 132] Viruses hamper 
the innate immune system with effects on neutrophil and macrophage recruitment and 
impairment of natural killer, antigen presenting and T-cell activity, leaving the mucosa at risk 
for bacterial invasion. [135-137] Viruses alter temperature and variably exhaust or increase 
the availability of micronutrients, which can allow bacteria in planktonic and biofilm form to 
proliferate. [150, 153] The general population, however, is subject to a near-constant 
onslaught from respiratory viruses but only 16% of individuals develop CRS. The link 
between these two entities may be related to the IFNs and their signalling pathways. These 
cytokines are expressed by almost all cells in response to pathogen invasion and play key 
roles in innate antiviral immunity. [239] Deficient IFN responses to viral infection have been 
consistently demonstrated in asthma, a similar disease process to CRS, as well as in CRS 
itself. [47, 63, 240] We hypothesise this lack of early antiviral activity in CRS patients may 
result in more frequent, severe or persistent viral infections, paving the way for the bacterial 
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invasion so critical for disease development. Further research, however, is required to clarify 
this hypothesis. 
 
Our results confirm a long-held suspicion that viruses are more common in CRS than in the 
general population. Viral presence is associated with more severe sinus disease measured by 
LMS and LKS. This has the potential to lead to exciting new developments in viral 
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CRSwNP patients frequently present with extensive eosinophilic inflammation, severe 
symptom scores and disease recalcitrance.  Different immune cell types and their secreted 
products are associated with tissue eosinophilia [199], however the initial insult causing the 
recruitment of these cells in CRS remains unclear. CD8+ T cells have been found to be 
enriched in CRS patients in association with eosinophilic disease. [205] In response to 
alloantigen encounter at mucosal surfaces, CD8+ T cells can be induced to express CD103. 
[207] CD103 expression is required for eosinophil recruitment in the context of allergic 
airway inflammation, and is associated with airway hyper-responsiveness. [205] Eosinophils 
are also recruited into the airways in response to viral infection to support innate host 
defence, while also contributing to the pathophysiology of disease [201]. CD8+ CD103+ T 
cells, also known as tissue-resident memory T cells (Trm cells) are thought to have a major 
role in viral immunity at mucosal surfaces. [241-243] 
 
As yet CD103+ cell subsets, including CD8+ CD103+  Trm cells, and their relationship to 
tissue eosinophilia and the presence of virus has not been investigated in CRS. In a recent 
study, we analysed the sinonasal virome in 288 CRS and control patients showing that 
viruses were more prevalent in CRS and were associated with significantly worse disease 
severity scores. [244] The present study utilised tissue samples from virus positive and virus 
negative CRS and control patients to investigate the number of eosinophils, CD8+, CD103+ 
and CD8+ CD103+  Trm cells in relation to viral infection. We hypothesised that these cell 







Viral sampling was undertaken from consented patients using mucosal cytology brushings of 
the left and right middle and inferior meatuses under endoscopic visualisation at the time of 
endoscopic sinus surgery. DNA/RNA extracts underwent PCR/RT-PCR testing for a panel of 
common respiratory viruses (AdV, BoV, CoV, EnV, influenza, MPV, PIV, RSV and RV). 
Mucosal samples were taken at the same time as the aforementioned swabs and processed to 
undergo Haematoxylin and Eosin (H and E) or immunofluorescence staining for eosinophils 
and CD8+ and CD103+ cells respectively (the differing methodology resulting in the two 
study arms). 
 
4.2.1 Study participants 
 
Patients were recruited from the tertiary rhinologic practices of two of the senior authors 
(PJW and AJP). This study was carried out in accordance with the recommendations of the 
Central Adelaide Local Health Network Ethics Committee, and the protocol was approved by 
the same (HREC/15/TQEH/132). Subjects gave written informed consent in accordance with 
the Declaration of Helsinki. Patients were included in this study if they were older than 
eighteen years of age and were undergoing endoscopic surgery. No patients in this study 
suffered from asthma or aspirin-exacerbated respiratory disease, none were smokers, none 
were on oral or topical steroids in the two weeks before the sample collection day, and none 
reported symptoms of viral illness in the two weeks before the sample collection day. Control 
patients did not have any clinical or radiologic evidence of CRS. CRS patients fulfilled the 




4.2.2 Viral sampling, processing and analysis 
 
Viral sampling, processing and analysis was undertaken using a previously published 
departmental protocol [238]. Briefly, endoscan cytology brushes (McFarlane Medical, 
Melbourne, Australia) were used to sample the left and right MM and IM mucosa with an 
aseptic technique and under endoscopic visualisation. Samples were transported on ice and 
stored at -80°C. Samples were thawed for processing and underwent RNA and DNA 
extraction using an AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany). These were 
again stored until real-time PCR batch testing for AdV, BoV, CoV, EnV, influenza, MPV, 
PIV, RSV and RV. An initial ERV3 assay was undertaken in the DNA extract fractions prior 
to assays for the disease-causing viruses to ensure adequate sample quality, and to ensure 
detection of active, intra-cellular viral DNA/RNA. Specifics regarding PCR target genes, 
primer and probe sequences and cycling conditions have also been detailed previously. [238] 
Viral detection was defined as a Ct of forty or less. 
 
4.2.3 Mucosal sampling, processing and analysis 
 
Mucosal tissue was harvested by sharp dissection with an aseptic technique as a routine part 
of patients’ endoscopic sinus surgery. Bony elements were removed from the tissue after 
which it was placed in transport medium (Dulbecco’s Modified Eagle Medium, Gibco by 
ThermoFisher, Waltham, USA) on ice. Once in the laboratory it was divided into small 
pieces and placed in 10% neutral buffered formalin for at least 24 hours, after which it was 
embedded in paraffin. These samples were cut into 5µm-thick slices, mounted on histological 
slides, stained with H and E and scanned using a NanoZoomer 2.0HT digital whole-slide 
imager (Hamamatsu, Japan). The images were then assessed by two blinded observers for 
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eosinophilia using previously described techniques. [246] In brief, images were scanned for 
areas of high cellular infiltration. Six areas of 0.035mm2 were selected from the subepithelial 
layer from each slide, eosinophils were counted and a mean eosinophil count was determined 
for each patient. 
 
A separate set of 5µm-thick slices were taken from a subset of the aforementioned paraffin 
blocks and mounted on histological slides for immunofluorescence microscopy.  Some 
patients had no further tissue available and so were not able to be included in this arm of the 
study. The slides were de-paraffinised by sequential immersion in solutions of xylene, 100% 
ethanol, 90% ethanol and PBS. Antigen retrieval was performed using a pressure-cooker 
method with the slides immersed in sodium citrate. Slides were washed with PBS and then 
blocked with serum-free blocker (Dako, Glostrup, Denmark) for 60 minutes at room 
temperature. CD8 and CD103 antibodies (clones CD/144B and EPR4166(2) respectively, 
both Abcam, Cambridge, UK) were diluted in 10% FCS TBST (1:5 dilution for the former 
and 1:250 for the latter). 50-100µL was added to each slide and incubated overnight at 4°C. 
Slides were washed twice in PBST in preparation for secondary antibody addition. These 
were anti-mouse IgG 647 and anti-rabbit IgG CY3, both diluted in 10% FCS TBST at a ratio 
of 1:200, and 50-100µL per slide. The slides were incubated for one hour at room 
temperature in the dark, and then washed twice with PBST. 200µg/mL of 4′,6-diamidino-2-
phenylindole (DAPI; Sigma, Aldrich) was added to resolve nuclei, and allowed to incubate 
for ten minutes at room temperature in the dark. The slides were rinsed twice in PBS, after 
which 50-100µL of TrueBlack dye (Biotium, Fremont, USA, diluted 1:20 in 70% ethanol) 
was added to reduce autofluorescence. The slides were washed a final three times in PBS 
after which a drop of anti-fade mounting medium (Dako, Glostrup, Denmark) was added 
before cover-slipping. Samples were visualised by using a LSM700 confocal laser scanning 
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microscope (Zeiss Microscopy, Jena, Germany). Images were assessed for T cell infiltration 
using the aforementioned eosinophil methodology. 
 
4.2.4 Statistical analysis 
 
Statistics were performed using R statistical software (R Foundation for Statistical 
Computing, Vienna, Austria) and the scientific Python package (scipy). Mann Whitney tests 
were used to compare means of inflammatory cell counts between various study groups and 
subgroups, with False Discovery Rate corrections for multiple comparisons. Multivariate 
permutation-based ANOVA models (as implemented in the R package ‘lmPerm’) were used 
to investigate the effect of the clinical covariates (disease phenotype, viral status) as well as 
their interaction terms, on the various mean inflammatory cell counts. Spearman tests were 
used to investigate any correlation between the eosinophils and the two T cell types. 



















4.3.1 Patient characteristics 
 
58 patients were recruited to the study: 6 controls, 33 CRSsNP and 19 CRSwNP. 30 were 
negative for any of the viruses tested (VN), and 28 were positive (VP). Patients in the 
different groups were matched for age, gender, disease phenotype and the season in which 
samples were taken (table 4.1). Eosinophils, CD8+ and CD103+ cell numbers were counted 
by two blinded observers; these are summarised in table 4.2. Viral species identified are 
summarised in table 4.3. 
 
Study arm Eosinophils T lymphocytes 








Diagnosis (control:CRSsNP:CRSwNP) 3:17:10 3:16:9 3:16:9 3:15:8 
Mean age (years) 50.6 49.9 50.9 49.8 
Sex (M:F) 19:11 19:9 17:11 17:9 
Season (spring:summer:autumn:winter) 10:6:9:5 8:6:9:5 8:6:9:5 8:5:9:4 
 






 Control CRSsNP CRSwNP 
 VN VP VN VP VN VP 
Mean eosinophil counts 0.28 1.94 0.20 1.76 1.02 4.65 
Mean CD8+ T cell counts 7.72 9.56 5.86 28.29 15.48 36.29 
Mean CD103+ T cell 
counts 
5.69 11.69 4.96 24.80 12.94 31.70 
Mean CD103+CD8+ 
Trm cell counts 
4.25 6.89 3.08 20.47 9.86 23.13 
 
Table 4.2 Mean cell counts. “VP” indicates virus-positive, “VN” indicates virus-negative. 
 
Study arm Eosinophils T lymphocytes 
Control BoVx1, CoV x2 As for eosinophil arm 
CRSsNP BoV x2, CoV x4, influenza A x5, 
RV x5 
BoV x2, CoV x4, influenza A x5, RV 
x4 
CRSwNP BoV x1, CoV x3, EnV x1, influenza 
A x1, RSV x1, RV x2 
BoV x1, CoV x3, influenza A x1, 
RSV x1, RV x2 
 
Table 4.3 Viral species identified. 
 
4.3.2 Viral detection and analysis 
 
Mean mucosal eosinophil, CD8+ T cells, CD103+ cells and CD8+CD103+ Trm cell counts 
were significantly greater in VP CRSsNP and VP CRSwNP than in their VN counterparts. 
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Eosinophils were significantly more abundant in VP CRSwNP than in VP controls. CD8+ T 
cells, CD103+ cells and CD8+CD103+ Trm cells were also significantly more abundant in VP 
CRSsNP and VP CRSwNP than in VP controls (figures 4.1 and 4.2). 
 
 
Figure 4.1 Mean cell counts of eosinophils (A), CD8+ cells (B), CD103+ cells (C) and 
CD8+ CD103+ Trm cells (D) in virus negative (-) and virus positive (+) controls (n = 6), 
CRSsNP (n = 17 top left, 16 elsewhere) and CRSwNP (n = 10 top left, 9 elsewhere) patients.   





Figure 4.2 Sinonasal mucosa of representative virus negative control (A, C) and virus 
positive CRSwNP patient (B, D). (A, B) Haematoxylin and Eosin stained tissue with 
eosinophils evident in inset image B (arrow indicates eosinophil). (C, D) 
immunofluorescence staining CD8+ T cells red, CD103+ cells green and CD8+ CD103+ Trm 
cells yellow/orange. DAPI stains nuclei blue. 
 
Bivariate permutation ANOVA models for each of the four cell types confirmed the 
significant association of disease phenotype and viral detection status with the outcome 
variables (inflammatory cell counts) in all four models. These models also showed a 
125 
 
significant interaction between disease phenotype and viral status in determining CD8+, 
CD103+ and CD8+CD103+ Trm cell counts (tables 4.4 to 4.7). 
 
Poisson model: Eosinophil average ~ factor (phenotype) + factor (virus) 


























• Null deviance: 141.491 on 53 degrees of freedom 
• Residual deviance:  72.907 on 50 degrees of freedom 
Table 4.4 Poisson model of eosinophil average. 
 
Poisson model: CD8+ T cell average ~ factor (phenotype) + factor (virus) 
Term Coefficient (β) Standard Error P value 
Intercept 1.23775 0.15030 < 0.0001 
Factor (phenotype) CRSsNP 0.87423 0.14521 < 0.0001 
Factor (phenotype) 
CRSwNP 
1.34350 0.14609 < 0.0001 
Factor (virus) 1 1.37696 0.06983 < 0.0001 
• Null deviance: 826.09 on 53 degrees of freedom 
• Residual deviance: 216.02 on 50 degrees of freedom 





Poisson model: CD103+ T cell average ~ factor (phenotype) + factor (virus) 
Term Coefficient (β) Standard Error P value 
Intercept 1.14435 0.15383 < 0.0001 
Factor (phenotype) CRSsNP 0.73168 0.14677 < 0.0001 
Factor (phenotype) 
CRSwNP 
1.19785 0.14782 < 0.0001 
Factor (virus) 1 1.48061 0.07755 < 0.0001 
• Null deviance: 725.42 on 53 degrees of freedom 
• Residual deviance: 162.89 on 50 degrees of freedom 
Table 4.6 Poisson model of CD103+ T cell average. 
 
Poisson model: DP Trm cell average ~ factor (phenotype) + factor (virus) 
 
















Factor (virus) 1 1.6048 0.0952 < 0.0001 
• Null deviance: 705.98 on 53 degrees of freedom 
• Residual deviance: 248.92 on 50 degrees of freedom 
 










This is the first study linking viral infection with tissue eosinophilia and accumulation of 
CD8+ T cells, CD103+ cells and CD8+CD103+ Trm cells in the context of CRS.  Strikingly, 
all four cell-types were increased in VP CRS patients compared to VP controls and our 
ANOVA multivariate analysis indicated that both viral status and CRS diagnosis positively 
affected inflammatory cell counts. The significant interaction terms in these models indicate 
that CRS patients might react to viral infection by inciting a more exacerbated immune 
response compared to controls and that viral infection might contribute to inflammatory cell 
infiltration in a subset of CRS patients. Both allergens and viruses are known to induce tissue 
eosinophilia and recent studies indicate CD103 expression plays a critical role in these 
processes [244, 247]. In line with these findings, this study also shows significantly increased 
CD103+ cell numbers in the presence of virus in CRS patients and controls. CD8+CD103+ 
Trm cells were also increased in VP CRS patients compared to VP controls and represented 
the majority of the total CD103+ cell population. Unlike Trm cells in the lung, Trm cells in 
nasal mucosa have been shown to develop independently of local antigen recognition and can 
persist for extended periods potentially explaining their presence also in VN patients. [248] 
Apart from expression on CD8+ T cell subpopulations, CD103 is also expressed on a subset 
of CD4+ T cells, natural killer cells and dendritic cells. [249] These cells have been reported 
to play host-protective roles in the context of infection and detrimental roles in the context of 
chronic inflammation. [249] Our study has some limitations. The exact role of CD103+ 
expressing cells including CD8+CD103+ Trm cells and their role in protection against viral 
infection and/or contribution to chronic inflammation in CRS is unknown and warrants 
further investigation. Also, the potential for causal relationships between viral infection of the 
sinuses and influx of eosinophils and CD8+ CD103+ Trm cells is not known. Thirdly, the 
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control group size in this study was small relative to the CRSsNP and CRSwNP groups; this 
is due to the rarity of viral positivity in control patients. 
 
In conclusion, this study links viral infection in CRS with mucosal eosinophilia and 
accumulation of CD8+ T cells, CD103+ T cells and CD8+ CD103+ Trm cells, implicating 
viruses as possible inciting factors in the dysregulated immune response in CRS. More 
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Background: Factors at play in the aetiopathogenesis of CRS have been postulated to include 
a bacterial dysbiosis and a recently established greater susceptibility to viral infection. There 
is potential for the presence of virus to influence the resident bacterial microbiome, thereby 
altering the course of the disease. The aim was to investigate virus-associated changes in the 
bacterial CRS sinonasal microbiome. 
Methods: Brushings of the sinonasal mucosa were taken at time of endoscopic sinus surgery. 
Viral detection was undertaken using PCR or RT-PCR on extracted DNA and RNA. Bacterial 
characterisation was undertaken using 16S ribosomal RNA gene-targeted amplicon 
sequencing. Analysis of bacterial abundance, diversity and stability with regard to viral 
presence was undertaken using the Quantitative Insights Into Microbial Ecology (QIIME 2) 
platform. 
Results: 82 adult patients were recruited for this study: 10 controls, 49 CRSsNP and 23 polyp 
CRSwNP patients. Half of each group was virus-positive. No significant differences were 
seen in relative abundances of the bacterial genera detected, their diversity or stability in any 
of the groups. A trend towards greater relative abundance of Haemophilus spp. was seen in 
patients reporting a viral illness two to four weeks prior, which was not apparent in patients 
reporting such between one and two months prior. 
Conclusion: No significant differences in the composition of the bacterial microbiome in 
virus-negative or positive patients was seen. A trend was seen towards early microbiome shift 







The bacterial microbiome of the aerodigestive tract and specifically the sinonasal passages is 
an area receiving increasing attention in current literature. This is of significant interest to 
research into CRS. This inflammation of the nose and paranasal sinuses of greater than 
twelve weeks duration is characterised by symptoms of anterior rhinorrhoea, PND, 
headaches, facial pain or pressure, nasal obstruction and hyposmia. Aetiopathogenesis 
theories are many but a significant focus remains on microbial imbalance, and methods of 
manipulating this for therapeutic ends.  
 
A bacterial dysbiosis has been shown to exist within CRS with patients showing a lack of 
biodiversity compared to healthy controls. [186] Bacterial species historically seen as more 
pathogenic are found to be relatively more prevalent in CRS than bacterial species that have 
been considered commensal. [187] Studies investigating the CRS microbiome have varied in 
scale, methodology and analysis and so data have been difficult to compare. Efforts have 
been made to standardise these, concluding that the healthy sinonasal microbiome consists 
mainly of Staphylococcus, Propionibacterium, Corynebacterium and Streptococcus species 
while the microbiome in CRS shows a reduction in the relative abundance of Actinobacteria 
and Propionibacterium species, with significantly more prevalent Corynebacterium species. 
[188] 
 
URT viruses have recently been shown to be more common in CRS than in healthy 
individuals. The presence of these viruses is also associated with more severe subjective and 
objective disease. [244] These findings potentially implicate viruses as an inciting and/or 
exacerbating factor in the immune dysregulation of CRS. Viral-bacterial co-infection is 
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known to have deleterious effects on epithelial barrier function, bacterial binding and innate 
and adaptive immunity. [114] It has been suggested that viruses may induce changes in the 
bacterial microbiome potentially causing more severe disease in the LRT. [191, 192] 
However, little is known about the specific changes in bacterial aerodigestive populations 
seen in the presence of viral infection in CRS. 
 
The aim of this study was thus to investigate virus-associated changes in the bacterial CRS 
sinonasal microbiome, , hypothesising that viral infection would indeed alter the composition 



















5.3 Materials and methods 
 
5.3.1 Study participants 
 
Study participants were recruited from the tertiary rhinologic practices of two of the senior 
authors (PJW and AJP). This study was carried out in accordance with the recommendations 
of the Central Adelaide Local Health Network Ethics Committee, with their approval of the 
protocol (HREC/15/TQEH/132). In accordance with the Declaration of Helsinki study 
participants gave written informed consent. Patients were included in this study if they were 
older than eighteen years of age and were undergoing endoscopic nasal surgery. Control 
patients did not have any clinical or radiologic evidence of CRS, and were undergoing trans-
sphenoidal resections of pituitary masses or surgery to the septum or ITs. CRS patients 
fulfilled the diagnostic criteria for CRS as outlined in the American guidelines, and were 
undergoing FESS. [245] Patients who had used antibiotics or steroids in the two months prior 
to the study day were excluded. No patients in this study suffered from asthma or aspirin-
exacerbated respiratory disease and none were smokers, On the study day patients were asked 
to report the timing of their last URTI with the following time points; current, within the last 
1-2 weeks, within the last 2-4 weeks, within the last 1-2 months, or more than 2 months prior. 
 
5.3.2 Viral sampling, processing and analysis 
 
Viral sampling, processing and analysis was undertaken using a previously published 
departmental protocol [238]. Briefly, the left and right MM and IM mucosa was sampled 
using endoscan cytology brushes (McFarlane Medical, Melbourne, Australia). This was 
conducted with endoscopic visualisation and aseptic technique. Samples were transported on 
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ice and stored at -80°C. At time of processing samples were thawed for RNA and DNA 
extraction using an AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. The products of these were stored and subsequently real-time 
PCR batch tested. An initial assay for ERV3 was undertaken in the DNA extract fractions to 
ensure adequate sample collection quality.  Assays were then undertaken for AdV, BoV, 
CoV, EnV, influenza, MPV, PIV, RSV and RV. PCR target genes, primer and probe 
sequences, the nature of positive and negative controls and cycling conditions have been 
published previously. [238] A Ct of forty or less indicated viral detection. 
 
5.3.3 Bacterial sampling and processing 
 
Bacterial sampling was also undertaken intra-operatively with an aseptic technique and 
endoscopic visualisation. Guarded, flocked swabs (Copan Italia S.p.A, Brescia, Italy) were 
inserted into the MMs of all patients on both sides and rotated seven times before removal. 
Swabs were stored at -80°C until batch thawing for DNA extraction and analysis as follows. 
Swab heads were cut into small pieces and 180µL of enzymatic lysis buffer (Qiagen, Hilden, 
Germany) was added and left overnight at room temperature. 5mm steel beads agitated for 20 
seconds at 15Hz in a Qiagen Tissue Lyser were used to homogenise the pieces, followed by 5 
minutes of further homogenisation with 0.1mm glass beads at 30Hz. DNA extraction was 
then undertaken in accordance with the Qiagen DNeasy Blood and Tissue Kit protocol 






5.3.4 Bacterial 16S-sequencing 
 
PCR amplification and sequencing were performed by the Australian Genomics Research 
Facility. Gene libraries were generated by amplifying the V3 to V4 (341F–806R) 
hypervariable region of the 16S rRNA. AmpliTaq Gold 360 Master Mix (Life Technologies, 
Mulgrave, Australia) with primers CCTAYGGGRBGCASCAG in the forward sequence and 
GGACTACNNGGGTATCTAAT in the reverse sequence were used to generate PCR 
amplicons. These underwent fluorometric measurement (Invitrogen Picogreen; Thermo 
Fisher Scientific, Waltham, MA, USA) and normalised. Quantitative PCR (KAPA 
Biosystems, Cape Town, South Africa) was used to quantify the equimolar pool. This was 
arranged for sequencing on the Illumina MiSeq (Illumina Inc., San Diego, CA, USA) with 
300 base paired end chemistry. All samples in this study were sequenced in one run. 
 
5.3.5 Bioinformatic pipeline 
 
QIIME 2 (version 2018.11) [250] was employed for the bioinformatic pipeline in this study. 
PEAR was used to combine forward and reverse reads [251] through the QIIME 2 plugin q2-
pear (https://github.com/bassio/q2-pear). The QIIME 2 plugin q2-quality-filter [252] was 
used to quality-filter the combined sequences. Minimum quality parameter was 20 [253]. 
Deblur (q2-deblur plugin with setting “trim-size” = 435 with default parameters otherwise) 
was used for denoising and to form Amplicon Sequence Variant (ASV). [253] Greengenes 
16S database (version 13.8 August 2013, the 99% clustered similarity sequences) was used as 
reference. [254] and the QIIME 2 BLAST-based q2-feature-classifier was used as taxonomy 




Prior to analysis, n=400 reads were chosen as the rarefaction depth cut-off. Rarefaction plots 
(for total number of ASVs and for Shannon's alpha diversity index) were performed (figure 
5.1). Relative abundance comparisons were done at the genus level. The taxonomic 
assignment of the one DNA-negative control sample containing extraction reagents only was 
explored. The bacterial genus Flavobacterium was present in high relative abundance in this 
sample and in relatively low abundance in many samples, so this genus was excluded before 
downstream statistical analyses. Mean relative abundance and genera prevalence were 
calculated. Alpha diversity was measured using Shannon’s diversity and Faith’s phylogenetic 




















Rank variability is a per-sample index, and a surrogate for microbiome stability. It is defined 
by Martí et al. as “the absolute difference between each taxon rank and the overall rank”. 
[257] Rank variability was calculated using a Python implementation of the equations 

























5.4.1 Patient characteristics 
 
82 patients were recruited: 10 controls, 49 CRSsNP and 23 CRSwNP. 41/82 patients were 
virus-positive: 5 control, 24 CRSsNP and 12 CRSwNP. Virus-positive and virus-negative 
patients were age and season-matched within the three groups (control, CRSsNP and 
CRSwNP). Demographics and patient characteristics are summarised in table 5.1. 
 
 Control CRSsNP CRSwNP 
Number with each diagnosis 10 49 23 
Number of virus-positive patients 5 24 12 
Mean age (years) 35.5 50.0 45.0 
Male: female 4:6 27:22 22:1 
Season sample obtained 
(spring:summer:autumn:winter) 
2:2:2:4 20:8:12:9 4:4:8:7 
 
Table 5.1 Summary of patient demographics and characteristics. 
 
5.4.2 Viral detection 
 
ERV3 was detected in all samples. Mean ERV3 Ct was 22.9, indicating that adequate cellular 
material was obtained in all cases. 41 patients were positive for one or more of the disease-
causing viruses assayed, while 41 were virus-negative. RV was the most prevalent of the 
species assayed; MPV was not detected in any of the samples. Fourteen patients were 
140 
 
positive for more than one viral species. Details of viral species detected are summarised in 
table 5.2. 
 
Viral species Number of positive 
control patients 
Number of positive 
CRSsNP patients  
Number of positive 
CRSwNP patients 
Adenovirus 1 0 0 
Bocavirus 1 2 1 
Coronavirus 4 6 5 
Enterovirus 1 1 1 
Influenza 0 6 1 
Parainfluenza 0 1 2 
Rhinovirus 1 13 1 
RSV 0 0 1 
 
Table 5.2 Details of viral species and patient diagnoses. 
 
5.4.3 Bacterial microbiome outcomes: taxonomy  
 
The most abundant taxa are found in table 5.3. The genera Corynebacterium, Staphylococcus, 
Streptococcus, Haemophilus, and Moraxella were the most abundant. We found no significant 
difference in differential abundance of the five most abundant genera by diagnosis (i.e. control 





 Control CRSsNP CRSwNP 
 Virus-pos Virus-neg Virus-pos Virus-neg Virus-pos Virus-neg 
 MRA P MRA P MRA P MRA P MRA P MRA P 
Corynebacterium 26.00 80.0 44.85 100.0 33.39 58.33 31.71 60.87 23.75 66.67 48.05 58.33 
Staphylococcus 47.06 80.0 33.05 100.0 22.45 58.33 24.49 69.57 26.85 66.67 23.55 50.00 
Streptococcus 9.12 20.0 0.00 0.0 4.86 12.50 9.94 26.09 0.00 0.00 3.62 16.67 
Haemophilus 0.00 0.0 0.00 0.0 10.55 16.67 3.50 8.70 5.42 8.33 0.00 0.00 
Moraxella 0.94 20.0 4.35 40.0 7.18 16.67 0.00 0.00 0.00 0.00 3.68 8.33 
Proteus 0.00 0.0 0.00 0.0 0.00 0.00 0.00 0.00 8.38 8.33 10.00 8.33 
Porphyromonas 0.00 0.0 0.00 0.0 6.11 8.33 0.00 0.00 3.60 8.33 0.00 0.00 
Genus unidentified 
(Enterobacteriaceae) 
1.25 20.0 0.00 0.0 3.11 12.50 4.84 4.35 0.00 0.00 0.00 0.00 
Alloiococcus 0.00 0.0 0.90 40.0 0.00 0.00 2.96 4.35 4.20 8.33 0.95 8.33 
Genus unidentified 
(Cytophagaceae) 
0.00 0.0 5.45 40.0 1.68 25.00 1.87 17.39 0.00 0.00 0.00 0.00 
 
Table 5.3 Summary of most abundant bacterial genera. “MRA” indicates mean relative 




Figure 5.2 Relative abundances of the most abundant bacterial genera. “v+” indicates viral 
positivity, “v-“ indicates viral negativity. 
 
5.4.4 Viral covariates as predictors of bacterial taxa abundances 
 
We found no significant association between viral presence or number of viruses detected and 
the abundances of the aforementioned most abundant bacterial genera (Kruskal-Wallis, p > 
0.05). Moreover there was no statistically significant association detected between the presence 
of CoV, influenza or RV and bacterial relative abundances. 
 
The above associations were again tested in a further subgroup analysis, with separate analyses 
for control, CRSsNP, and CRSwNP groups. This yielded no significant associations in any of 
the three patient groups (p > 0.05). However, a trend towards a shift in bacterial microbiome 
composition manifest as a greater relative abundance of Haemophilus spp. was seen in patients 
reporting a viral URTI two to four weeks prior to the study day (figure 5.3). 
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Figure 5.3 Relative abundances of the most abundant bacteria grouped by time since last 
patient-reported viral infection. 
 
5.4.5 Viral covariates as predictors of bacterial diversity and stability 
 
We calculated Faith’s and Shannon’s indices as markers of both phylogenetic and non-
phylogenetic alpha diversity. We also calculated rank variability; a per-sample surrogate for 
microbiome stability as mentioned earlier. We found no significant association between 
bacterial genera abundances and viral status covariates such as viral presence, number of 










This study seeks to compare the bacterial microbiome seen in virus-positive and virus-
negative individuals both with and without CRS. The most prevalent viruses seen in all 
groups were CoV, influenza and RV. The most abundant bacterial genera seen were 
Corynebacterium, Staphylococcus, Streptococcus, Haemophilus, and Moraxella. We 
observed a trend towards changes in the microbiome in patients reporting a viral infection 
less than a month prior to the study date. This trend was not seen in patients reporting their 
last viral infection more than a month prior. This may indicate an early shift in the 
microbiome associated with viral infection, which may then normalise after a month. Despite 
a lack of significance in this small sample size, this may indicate a tendency towards 
superinfection and worsening of disease in the CRS population. Greater investigation with a 
larger sample size and repeat sampling over time is required to elucidate this further. A 
longitudinal, prospective model would be required in order to confirm initial viral infection; 
our findings were based purely on patient-suspected pathology. 
 
No significant differences were seen in bacterial abundance, diversity or stability between 
virus-negative or virus-positive individuals within the control, CRSsNP or CRSwNP groups 
with regard to the other viral covariates tested (presence or absence of virus, number of 
viruses or presence of specific viruses). This is in contrast to previously reported effects of 
viral presence on the microbiome in non-CRS populations [258-260]. Our study focuses on 
CRS patients, is smaller and geographically different to these studies, but its strengths lie in a 
robust and previously validated viral collection method, [238] an undertaking of more in-
depth analysis beyond viral presence or absence alone, and the use of age and season-
matched virus-negative control groups. Ding et al. compared swabs from control and 
145 
 
influenza-infected individuals (sample size of 40 versus 215). They found Corynebacterium 
and Streptococcus to be more abundant in controls, with virus-positive swabs dominated by 
Moraxella and Dolosigranulum. [260] This result is interesting not least due to the rarity of 
identification of Dolosigranulum in adult CRS URT bacterial profiles; the low biomass of 
airway samples carries risk of contamination if not carefully screened prior to and following 
analysis. Borges et al. compared swabs from twelve patients with severe acute respiratory 
infections: six with influenza, and six with undisclosed non-influenza causative viral 
organisms. Despite their small sample size they found significant differences in abundance of 
fifteen different bacterial genera, however no control group was presented. [259]  Rosas-
Salazar et al. compared the infantile microbiome in the presence of either RV or RSV, and 
found significant differences in eleven genera. Again, no control group was presented, and in 
all three of the aforementioned studies viral collection methods were prone to contamination. 
No method to ensure cellular collection was employed, and as such even viral presence 
cannot be confidently asserted in these studies. 
 
The negative effects of a viral/bacterial co-infection have long been established in many body 
systems, but of significant interest in any such co-infection model is the nature of the original 
inciting pathogen. This is a cross-sectional study investigating the characteristics of sinonasal 
microbiota at a solitary time point (that of endoscopic sinonasal surgery). Should differences 
in these microbiota have been observed between control and CRS patients, we would be 
unable to determine whether it is the composition of the bacterial microbiome that 
predisposes to viral infection, or vice versa. To elicit such information a longitudinal study 
model would be required. To our knowledge this has not yet been undertaken in these 
cohorts. An additional limitation is a lack of gender balance in the CRSwNP patient sample, 
and the known differing immune response profile of CRSsNP and CRSwNP patients. 
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CRSsNP is associated with a Th-1 skewed response, while CRSwNP is associated with a Th-
2 skewed, eosinophilic response. [34, 35] Viral infections themselves are also associated with 
eosinophilia. [247] These factors have the potential to impact the detection of virus and/or the 
microbiome balance observed in this study. [261] 
 
Of additional interest but requiring further research would be whether there is indeed 
correlation between patient reporting of a current viral infection, and the presence of virus in 
the sinonasal passages at that time. Only three patients in this study reported such, limiting 
any analyses thereof. An additional limitation is that the symptoms of CRS and of a viral 
URTI are indeed similar but with a marked difference in duration. 
 
In conclusion this study compares the bacterial microbiome in virus negative and virus 
positive controls, CRSsNP and CRSwNP, and has uncovered no significant differences in its 
composition. However, a trend towards early microbiome shift in patients who report a recent 
viral infection has been uncovered. Larger, longitudinal investigation is required to 











Thesis synopsis and future directions 
 
 
This thesis provides novel insights into the role of viruses in CRS. We have first established a 
robust, reproducible and validated collection method for sinonasal viruses. We then finally 
established that viruses are indeed more common in CRS than in the general population, and 
that their presence is associated with more severe disease. We showed that virus-positive 
CRS is associated with eosinophil and CD8+, CD103+ and double-positive T cell presence in 
excess of that seen in virus-positive controls. This implicates viruses as a possible inciting 
factor in the dysregulated innate and adaptive immune responses seen in CRS. Our final 
study uncovers a trend towards early bacterial microbiome shift in the context of recent viral 
infection, which may represent a nidus for superinfection contributing to the development of 
CRS.  
 
The research presented in this work is but a gateway to potential further investigation. We 
live in an era of increasing antibiotic resistance with emergence of novel pathogens (both 
viral and bacterial) and widely accessible long-distance travel enabling pandemics. This work 
was undertaken, and indeed the last sentence written, prior to the CoVID-19 outbreak; never 
has this been so clearly demonstrated. As such, intimate knowledge of both healthy and 
disease-inducing microbes, and the interplay amongst these, is essential to rationalise targets 
and develop new prevention and therapeutic strategies. Not least of these are vaccines and 
early antiviral therapy for those at risk. An exciting area in need of more research is the role 
of interferons in the post-viral immune cascade. The development of small-molecule 
modulators is still in its infancy but shows promise in malignancy, and as such these could be 
promising as anti-viral pharmacological agents in CRS. Information is also lacking with 
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regards the response of a previously bacterially infected or colonised airway to secondary 
viral infection, and the contribution of fungus to this and  airway immune functions. It is also 
very difficult to simulate the constantly-barraged, highly unsterile human respiratory 
environment; no viral or bacterial infection ever takes hold without the simultaneous presence 
of multiple other colonisers and/or pathogens. Greater knowledge of the healthy and diseased 
human respiratory microbiomes will allow more accurate investigation of the interplay 
amongst viruses, bacteria, fungi, bacteriophage and protozoa.  
 
More research is needed to elucidate the cause-consequence relationship of CRS and viruses. 
The mechanism behind increased rate of viral infections in CRS also remains to be seen. In 
this thesis we postulate this may be related to defective IFN responses to viral infection in 
CRS populations. Characterisation of these responses is needed; this may lead to 
manipulation of IFN in CRS as a therapeutic strategy in a disease that remains so very 
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